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ABSTRACT  
   
Glycans are monosaccharide-based heteropolymers that are found covalently attached to 
many different proteins and lipids and are ubiquitously displayed on the exterior 
surfaces of cells. Serum glycan composition and structure are well known to be altered in 
many different types of cancer. In fact, glycans represent a promising but only 
marginally accessed source of cancer markers. The approach used in this dissertation, 
which is referred to as “glycan node analysis”, is a molecularly bottom-up approach to 
plasma/serum (P/S) glycomics based on glycan linkage analysis that captures features 
such as α2-6 sialylation, β1-6 branching, and core fucosylation as single analytical 
signals.  
The diagnostic utility of this approach as applied to lung cancer patients across 
all stages as well as prostate, serous ovarian, and pancreatic cancer patients compared to 
certifiably healthy individuals, nominally healthy individuals and/or risk-matched 
controls is reported. Markers for terminal fucosylation, α2-6 sialylation, β1-4 branching, 
β1-6 branching and outer-arm fucosylation were most able to differentiate cases from 
controls. These markers behaved in a stage-dependent manner in lung cancer as well as 
other types of cancer. Using a Cox proportional hazards regression model, the ability of 
these markers to predict progression and survival in lung cancer patients was assessed. 
In addition, the potential mechanistic role of aberrant P/S glycans in cancer progression 
is discussed.  
Plasma samples from former bladder cancer patients with currently no evidence 
of disease (NED), non-muscle invasive bladder cancer (NMIBC), and muscle invasive 
bladder cancer (MIBC) along with certifiably healthy controls were analyzed. Markers for 
α2-6 sialylation, β1-4 branching, β1-6 branching, and outer-arm fucosylation were able 
to separate current and former (NED) cases from controls; but NED, NMIBC, and MIBC 
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were not distinguished from one another. Markers for α2-6 sialylation and β1-6 
branching were able to predict recurrence from the NED state using a Cox proportional 
hazards regression model adjusted for age, gender, and time from cancer. These two 
glycan features were found to be correlated to the concentration of C-reactive protein, a 
known prognostic marker for bladder cancer, further strengthening the link between 
inflammation and abnormal plasma protein glycosylation. 
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CHAPTER 1 
INTRODUCTION 
1.1 The Structure, Biological Function, and Importance of Glycans 
Glycans are one of the abundant and diverse natural biopolymers. In biological systems, 
glycans are attached to proteins and lipids displayed on exterior surface of cells and 
macromolecules consisting variety of structures. Glycans are produced by 
glycosyltransfeases in the endoplasmic reticulum (ER) and golgi apparatus organelles.  
Studies on glycan functions show that enzymes such as glycosyltransferases and 
glycosidases have important role in the development and physiology of living organisms 
[1]. Glycans are involved in such diverse important biological processes as cell adhesion, 
signal transduction, molecular recognition, receptor activation, endocytosis, and 
molecular trafficking and clearance. Glycobiology is the field of studying and 
understanding the structure and biological function of glycans. The science of protein 
expression, modification, interaction and function in biological systems, proteomics, has 
had a major growth over the years; however, proteins’ post-translational modifications 
which happen in majority of proteins in eukaryotic cells have not been significantly 
studied until recently [2]. One of the most common and complex post-translational 
modifications is glycosylation, which has an essential role in cell viability. 
 
1.1.1 Types of Glycans 
The three major classes of glycans include N-linked glycans, O-linked glycans, and 
glycolipids (Figure 1.1). N-linked glycans are attached to the nitrogen atom of aspargine 
residues with an amino acid sequence of Asn-X-Ser/Thr where X can be any amino acid 
except proline. O-linked glycans are usually attached to the oxygen atom of serine or 
threonine residues on the protein. A common type of protein O-glycosylation is mucine 
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type O-glycosylation in which the O-glycan is attached via N-acetylgalactosamine (O-
GalNAc). There are also other types of O-glycosylation that are initiated via mannose or 
N-acetylglucosamine (GlcNAc). Moreover, some forms of glycosylation only occur in 
specific types of proteins, such as the Notch receptors that are usually modified with 
different O-glycans including O-fucose (Figure 1.1) [3]. Lipid-linked glycans are usually 
attached to a sphingolipid or a glycerol group that consists of one or two fatty acids. 
Glycosylphosphatidylinositol (GPI) is a lipid-linked glycan that is usually attached to the 
C-terminus of a protein. These GPI-anchored proteins can be found on the cell plasma 
membrane (Figure 1.1). There is another class of glycoconjugates called proteoglycans 
that have one or multiple glycosaminoglycans (GAGs) (Figure 1.1). Heparan sulphate, 
hyaluronan, and chondroitin sulfate are some of the most important GAGs in human 
body.  
In order to analyze the peptides or the glycans attached to glycoproteins, 
removing the oligosaccharide structures from glycoproteins facilitates the process. There 
are highly efficient methods, both chemical and enzymatic, to separate oligosaccharides 
from glycoproteins. Chemical methods usually cause degradation of proteins. For 
instance, in solid phase permethylation, O-glycans are released from proteins using 
iodomethane in sodium hydroxide beads but it also results in degradation of the protein 
[4]. Enzymatic methods are softer compared to chemical methods. For example, to 
release N-glycans from glycoproteins, PNGase F enzyme is the most efficient. It releases 
the N-glycans by hydrolyzing the glycan chain from glycoproteins as well as deamination 
of asparagine to aspartic acid [5]. Enzymatic methods of releasing O-glycans are more 
challenging. Most often, a series of exoglycosidase digestions or a combination of 
enzymatic/chemical release must be carried out to release O-glycans from glycoproteins 
[4]. Song et al. have recently developed a simple approach to release N- and O-glycans 
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from kilogram amounts of biological samples [6]. In this method, which is termed 
“Oxidative release of Natural Glycans”, biological samples are treated in a controlled 
condition with sodium hypochlorite (NaClO) found in commercial bleach to selectively 
release N- and O-Glycans, which then can be tagged specifically for chromatographic 
separation and structural elucidation [6]. 
 
1.1.2 Biological Functions of Glycans 
In order to understand the biological functions of glycans a variety of approaches can be 
taken including chemical or enzymatic removal of the intact glycan structures from 
glycoproteins, manipulation of glycan processing, and elimination of glycosylation sites 
genetically. Based on the results of the aforementioned approaches taken by scientists 
over the years, glycan roles can be classified into four general categories: structural and 
modulatory roles, exogenous (extrinsic) recognition, endogenous (intrinsic) recognition, 
and molecular mimicry of host glycans (Figure 1.2) [1]. Each of these roles is discussed 
with examples here. 
 
1.1.2.1 Structural and Modulatory Roles 
Structural features of glycans mediate some essential biological effects since glycans have 
a broad presence with considerable abundance in intra- and extracellular areas and body 
fluids. For instance, the toughness and strength of plants and cell walls of fungi come 
from some glycan polymers such as cellulose and chitin, which are β-linked 
homopolymers of glucose and N-acetylglucosamine, respectively [7], [8]. In another 
example, glycocalyx, a heterogeneous group of glycoprotein covering all eukaryotic cells, 
has a major role as a physical barrier [9], [10].
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Furthermore, glycans are able to alter the function of proteins and lipids that are 
attached to them. Glycoprotein folding is one of the mechanisms in which glycans have 
an important role. More than 50% of the proteins synthesized via secretory pathway are 
glycosylated. Glycosylation of these proteins facilitates their folding. Most of the ER-
synthetized proteins are glycosylated by N-glycans. Considering their large hydrophilic 
structures, these N-glycans should be involved in proper folding of the synthetized 
polypeptides. In 1977, Leavitt et al. examined the effect of N-linked glycans on folding of 
these proteins [11]. Unlike the glycosylated forms, the nonglycosylated glycoproteins of 
vesicular stomatitis virus and sindbis virus could not be detected on the outside of the 
plasma membrane. The inhibition of N-linked glycosylation of these glycoproteins using 
tunicanycin resulted in improper folding of such proteins, leading to their inability to 
migrate to the cell surface [11]. 
Studies indicate that not only can the signaling characteristics of protein 
receptors be affected by glycoproteins and glycolipids that are in the same cell 
membrane, but also they can change by glycans attached to these proteins and lipids. In 
1991, Rapraeger et al. found out that by preventing heparan sulfate at the cell surface to 
bind to basic fibroblast growth factor (bFGF), the binding of FGF to its receptors with 
tyrosine kinase activity significantly decreases [12]. As another example, a study in 2005 
by Wang et al. showed alteration in core fucosylation of N-glycans of TGF –β1 receptors 
can lead to emphysema by causing over-expression of matrix metalloproteinases 
(MMPs) [13]. 
Another function of glycans is protection from immune recognition. The foreign 
proteins can be recognized by B cell receptors. Also, they can be coupled with major 
histocompatibility receptors following recognition by T cell receptors. Peptides 
containing small glycans can be recognized by glycopeptide-specific cytotoxic T cells 
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[14]; however, peptides with larger glycans can usually escape the major 
histocompatibility coupling and T cell receptor recognition. For instance, influenza 
hemagglutinin that is heavily glycosylated uses this strategy to evade immune system 
[15]. 
The N-glycans attached to glycoproteins on cell surfaces can have different 
number of branches. Not only glycan branching can change the structure of the protein 
that it is attached to, but also it can change various biological functions. As Demetriou et 
al. reported in 2001, N-glycan branching increases activation of T cell [16]. In addition, 
β1-6 branching is directly involved in malignant transformation. It is shown that 
introducing increased β1-6 branching to mouse models with nonmetastatic breast cancer 
significantly increased their metastatic potential [17]. Another type of N-glycan 
branching that is called bisecting GlcNAc, is involved in inhibition of growth factor 
signaling, which leads to reducing the progression of mammary tumor [18]. E-cadherin, 
showing this type of abnormal glycosylation, is classified as a tumor suppressor and it is 
reported as a potential diagnostic biomarker in breast cancer [19]. N-glycan branching 
occurs by addition of β-linked GlcNAc residues that are provided by UDP-GlcNAc. The 
concentration of UDP-GlcNAc is related to the distribution of glycoproteins at the cell 
surface, cellular metabolism, and some diseases since glucosamine and GlcNAc have 
important metabolic effects in most cells [20]. Lau et al. reported that the number of N-
glycans and degree of branching on a glycoprotein is associated with cellular transition 
between growth and cell cycle arrest and differentiation [21]. 
 
1.1.2.2 Exogenous Recognition 
Over the time, a lot of pathogens and symbionts have evolved glycan-binding proteins to 
recognize specific glycans on the complex cell surface of the host species. These 
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interactions that usually occur through glycan binding proteins can cause symbiosis or 
disease. For instance, Helicobacter pylori that has an important role in gastric ulcer and 
cancer, recognizes the gastric sialoglycans adhering to the gastric epithelial lining. This 
bacterial adherence can be mediated by fucosylated Lewis b histo-blood group antigen 
[22]. One of the well-characterized bacterial adhesins is FimH, which mediates the 
adhesion of uropathogenic E coli to urothelial cells by binding to D-mannose. 
Uropathogenic E coli is accountable for urinary tract infections that are mostly treated 
with antibiotics. Since antibiotics develop high risk of resistance, Jiang et al. proposed a 
new class of antimicrobials, which target FimH. Based on their experiments, 
indolinyphenyl mannoside was the most efficient antimicrobial targeting FimH, 
reducing the colony-forming units in the bladder of mouse models significantly 
compared to the common treatment with ciprofloxacin antibiotic [23]. 
 In addition to bacterial adhesins, parasite and fungal adhesins are responsible for 
some serious diseases. For example, plasmodium falciparum malaria parasites infect the 
red blood cells by recognizing N-acetylneuraminic acids (Neu5Ac) attached to 
glycophorins on the target red blood cells [24]. As fungal adhesins, epithelial adhesion 
(EPA) family that are encoded mostly by the Candida glabrata genome, are accountable 
for mediating attachment to host cells. Epa1, Epa6, and Epa7 are adhesins of Candida 
glabrata that recognize ligands containing a terminal galactose residue [25]. 
 Glycans can mediate the adjustment of host immune responses to parasites or 
symbionts. For instance, polysaccharide A that comes from major mammalian gut 
microbiome members helps cellular and physical maturation of immune system by 
improving T cell deficiencies and controlling lymphoid organogenesis [26]. Similarly, 
glycans expressed by parasitic helminthes interact with host glycan binding proteins to 
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adjust innate and adaptive immune responses in order to promote their survival, a 
concept known as “glycan gimmickry” [27]. 
 Glycans can facilitate antigen recognition, uptake, and processing. As an 
example, foreign proteins with significant amount of terminal mannose and N-acetyl 
glucosamine (GlcNAc) residues attached to them can activate phagocytosis through C-
type lectin receptors expressed on antigen-presenting cells resulting in activation of 
immune responses [28]. As another form of non-self recognition, CD1 molecules that 
present foreign glycolipids can be recognized by invariant T cell antigen receptor 
expressed by natural killer T lymphocytes [29]. 
 
1.1.2.3 Endogenous Recognition 
Glycans function as specific ligands not only for cell-microbe interactions but also for 
cell-cell interaction within the same species. The first glycan receptors discovered with 
intrinsic recognition were those containing mannose-6-phosphate, which are recognized 
by P-type lectins leading to mediation of lysosomal enzyme trafficking to lysosomes [30]. 
So far, various glycan-binding proteins have been discovered that have intrinsic 
functions mediating different biological processes. 
 Aside from their role in nascent glycoprotein folding mentioned earlier, glycans 
are involved in ER associated degradation (ERAD). For example, the lipid-linked 
oligosaccharide donor for N-glycosylation that has the same structure 
(Glc3Man9GlcNAc2-P-P-dolichol) [31] in nearly all eukaryotes plays an important role 
during glycoprotein folding in ER. In 1983, Parodi et al. found a 
glucosylation/deglucosylation cycle in this process in which the third glucose residue is 
regularly detached and then attached again [32]. Later in 1994, it was discovered that 
calnexin and calreticulin, ER chaperones, recognize monoglucosydated oligosaccharides 
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on glycoproteins [33]. After removal of the last glycose residue, the oligomannose N- 
glycans can be recognized by mannose 6-phosphate receptors of some chaperone 
proteins [34]. Ultimately, a series of N-glycan dependent quality controls determine 
whether a glycoprotein will continue in the secretory pathway or will be sent for ERAD. 
 Similar to mannose 6-phosphate recognition by P-type lectins for lysosomal 
enzyme trafficking, there are other molecules like lectin in the secretory pathway that 
regulate intracellular glycoprotein trafficking. For instance, ERGIC-53 that is a 
mannose-binding and calcium-dependent human homolog of leguminous lectins 
localized to the ER-Golgi intermediate compartment, when forming a complex with 
MCFD2, builds a specific cargo receptor for ER to Golgi transportation of selected 
glycoproteins such as factor V and factor VIII clotting proteins [35]. 
 Glycans are also involved in triggering endocytosis. Different known lectins 
perform endocytosis in macrophages and antigen-presenting cells. In addition to T cell 
activation, this process is important for damaged cells and glycoprotein clearance. For 
example, in case of cancer and inflammation heterogeneously O-glycosylated mucins 
aberrantly enter the bloodstream; however, the circulating mucins that are used as 
clinical diagnostic markers are only the clearance-resistant subset of these molecules and 
most of the secretory mucins entering the circulation are cleared by multiple glycan 
recognizing hepatic clearance receptors [36]. 
 The role of glycans in intercellular signaling is essential. Bacterial Nod factors 
that are lipo-chitooligosaccharides (LCO) are well known for communicating signals 
produced by rhizobial bacteria and recognized by lysine-motif receptors in the roots of 
legumes. This process activates the common symbiotic pathway, which eventually results 
in production of nodules on the root and nitrogen fixation. Nod factors also participate 
in recognition of plant pathogenic microorganisms [37]. 
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 Intercellular adhesion is among important glycan functions. Selectins are 
transmembrane glycoproteins that bind to focusylated and sialylated glycoproteins 
mediating leukocytes adhesion to the vascular endothelium. Since selectin interactions 
have an important role in cancer and inflammation, targeting them for treatment of such 
pathological conditions can be useful. For example, oral use of fucose proved helpful in 
correction of leukocyte adhesion deficiency-II by increasing the expression of fucosylated 
selectin ligands on the surface of neutrophils [38]. In another example, the pan-selectin 
inhibitor GMI-1070 reduces selectin mediated cell adhesion and abrogates sickle cell 
crisis in animal models [39]. 
 
1.1.2.4 Molecular Mimicry of Host Glycans 
Glycans can serve as pathogen associated molecular patterns (PAMPs), which can be 
detected by pattern recognition receptors of innate immune cells such as NOD-like 
receptors and C-type lectins. Glycans can also inhibit immune response by acting as self-
associated molecular patterns (SAMPs) that are recognized by intrinsic inhibitory 
receptors. The evolution of microorganisms has resulted in phenomenal molecular 
mimicry of host glycans. For instance, the structure of Group B Streptococcus (GBS) 
polysaccharides include Neu5Acα2-3Galβ1-4GlcNAcβ1- unit, which is in common with 
the structure of host glycans. It has been shown that Siglec-9 interacts with sialic acids 
on GBS the same way it does with host sialic acids, inhibiting neutrophil responses [40].  
 Sialoglycan mimicry by microorganisms can be done in different ways. Some of 
them like Psseudomonas aeruginosa adsorb sialoglycoproteins [41] and some others 
such as Haemophilus influenzae acquire the free sialic acids in their environment [42]. 
Also, there is another group of microorganisms like Trypanosoma cruzi that use trans-
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sialidases to transfer host sialic acids to the terminal β-galactopyranosyl residues of 
mucin-like molecules on the cell surface of the parasite [43]. 
 
1.2 Alteration of Glycans in Cancer 
Nearly all tumor cells display aberrant glycan structures. Since abnormal glycan 
modifications are unique for each protein, glycosylation site, and cell, the molecular and 
functional diversity increases within cell population. There are different factors in 
glycosylation process that affect formation of the final glycan structure in a specific cell 
or tissue type. The two major concepts for tumor-associated alterations of glycan 
structures are incomplete synthesis and neo-synthesis, which were formulated by 
Hakomori et al. in 1983. The incomplete synthesis process usually happens in early 
stages of cancer as a result of the destruction of normal synthesis of glycan structures 
expressed in normal epithelial cells, leading to formation of truncated structures. For 
example, abnormal synthesis of sialyl-Tn antigen, which occurs due to the 
overexpression of ST6GalNAc I, changes the glycosylation pattern of tumor cells in 
breast cancer, resulting in decreasing their adhesion and increasing their migration [44]. 
Neo-synthesis that most often occurs in late stage cancers is a consequence of induction 
of transcription of certain important glycogenes. For instance, expression of sialyl Lewis 
a (SLea) and SLex is induced in advanced stages of several cancers by hypoxia induced 
transcription of the genes involved in the expression of these carbohydrate determinants 
[45]. 
 One of the important upstream causes of altered glycans expression is under- or 
overexpression of glycosyltransferases (GTs), which is a result of transcriptional 
dysregulation [46], chaperone dysfunction [47], and/or altered glycosidase activity [48]. 
In fact, dysregulation of glycosyltrasferase activity is a hallmark of almost every known 
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type of cancer [49]. In addition, changes in the tertiary structure of the peptide backbone 
and/or the attached glycan chain can lead to altered expression of glycans. Besides, since 
individual glycosyltrasferase enzymes show strict donor, acceptor, and linkage 
specificity, the acceptor substrate, availability and abundance of the sugar-nucleotide 
donors, and expression and localization of proper GTs in the Golgi apparatus can 
contribute to changing the glycan expression [50]. 
 Glycosylation changes that are related to cancer can be divided into five 
categories: sialylation, fucosylation, N-glycan branching and bisecting GlcNAc, and O-
glycan truncation. 
 Sialylation plays an essential role in cellular recognition, cell signaling and cell 
adhesion. It has been shown that in cancer, abnormal GT expression leads to an increase 
in α2,6- and α2,3-linked sialylation [51]. For example, the expression of β-galactoside 
α2,6-sialyltransferase I (ST6Gal-I) that synthesizes α2,6-sialylated lactosamine 
(Sia6LacNAc) is altered in different cancers such as colon, stomach, and ovarian cancer 
and has been shown to be a predictive marker of poor prognosis in colon cancer [52], 
[53]. Another important sialylated antigen is SLex, which is overexpressed in several 
malignant cancers and its expression level can be predictive of patients’ survival [54]. 
Overexpressed SLex promotes the development of metastasis by interacting with 
selectins in cancer, forming bulks of cancer cells and facilitating their adhesion to 
endothelia [55]. 
 Another glycosylation factor associated with cancer is fucosylation. There are two 
types of fucosylations: terminal fucosylation and core fucosylation. In the biosynthesis of 
SLe antigens, the terminal steps consist of α1,3- or α1,4-focusylation of SLea or SLex that 
are α2,3-sialylated [56]. It has been reported that the increased expression of SLex in 
breast tumors is dependent mainly on the activity of Fuc-TVI, a fucosyltransferase 
  12 
enzyme encoded by FUT6 [57]. As another example, Fuc-TVII regulates the expression of 
SLex in adult T cell leukaemia cells. The human T-lymphotropic virus I retrovirus 
encodes TAX, a transcriptional activator protein, which modulates the FUT7, the gene 
that encodes Fuc-TVII [58]. In core fucosylation, α1,6-fucose is added to the GlcNAc 
residue at the N-glycans core by Fuc-TVIII, a fucosyltransferase encoded by FUT8. In 
several cancers including lung cancer, enhanced expression of FUT8 and core 
fucosylation is a major feature [59]. Core fucosylation of α-fetoprotein in hepatocellular 
carcinoma (HCC) facilitates the early diagnosis of this disease. In fact, it is an approved 
biomarker for HCC that can distinguish it from chronic hepatitis and liver cirrhosis [60]. 
 Branching and bisecting GlcNAc N-glycans are also among common feature of 
tumors. During malignant transformation the activity of GnT-V increases. As a result, 
β1,6-branched N-linked glycans are overexpressed in cancer cells. It has been shown that 
the gene encoding GnT-V, MGAT5, is regulated by the RAS-RAF-MAPK signaling 
pathway, which is activated in cancer [17]. For instance, an immortalized lung epithelial 
cell line transfected with a GnT-V expressing vector exhibited characteristics of cellular 
transformation such as loss of contact inhibition, increased cell motility and tumor 
formation in nude mice [61]. Moreover, downregulation of GnT-V in cancer cell lines 
leads to suppression of tumor progression and metastasis. Mammary tumor growth and 
metastases induced by a viral oncogene was significantly less in Mgat5 deficient mice 
than in transgenic littermates expressing Mgat5 [62]. GnT-III, which is encoded by 
MGAT3 and is responsible for adding bisecting GlcNAc N-glycans in a β1,4-linkage, has a 
tumor suppressive role as opposed to GnT-V. For example, transfection of MGAT3 into 
highly metastatic murine melanoma cells resulted in a significant suppression of lung 
metastasis in syngeneic and nude mice. Also, due to GnT-III and GnT-V competition for 
substrate β1,6-branching was significantly decreased [63].  
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 Overexpression of truncated O-glycans is another characteristic of tumors. The 
mucin-type O-glycans, which are initiated by polypeptide GalNAc transferases 
(ppGalNAcTs) are usually found in most transmembrane and secreted glycoproteins 
[64]. The expression of ppGalNAcTs is usually altered in cancer leading to abnormal O-
glycosylation [65]. Furthermore, competition of enzymes for the same substrate can lead 
to overexpression of truncated glycans, exposing protein epitopes that would be hidden 
in normal conditions. For instance, the relative enzymatic activities of C2GnT1 and 
ST3Gal-I indicate the dominant O-glycan structure and control the expression of a 
tumor-associated epitope, SM3, on MUC1 [66]. It has been shown that truncated O-
glycan structures Tn and Sialyl-Tn are associated with oncogenic features, such as 
enhanced tumor growth, decreased cell adhesion and invasion [67]. Since Sialyl-Tn can 
be detected in most carcinomas as opposed to healthy tissues, it has been considered as a 
potential prognostic marker and a target of cancer vaccines [68]. 
 
1.3 Glycans in Cancer Diagnosis 
Cancer is one of the leading causes of death in the world. There is an essential need for 
new approaches toward risk prediction, early diagnosis, and treatment of cancer. 
Recently, glycans have proven to be a promising source for the development of new non-
invasive biomarkers. 
 Currently, some of the clinically approved biomarkers that are being used for 
cancer diagnosis and prognosis are glycoproteins [69]. For example, prostate-specific 
antigen (PSA) is a biomarker widely used for prostate cancer diagnosis [70]. Other 
instances of glycoprotein biomarkers include: carcinoma antigen 125 (CA125) for ovarian 
cancer [71], SLea and CA19-9 for colon, gastric, and pancreatic cancers [69], [72], and 
aberrantly glycosylated MUC1, also known as CA15-3, for breast cancer [73].  Due to 
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their relatively low specificity, all of the aforementioned serological biomarkers have 
restricted application. This issue has encouraged a search for new biomarkers with 
higher specificity and sensitivity for early diagnosis of cancer based on detection and 
quantification of specific glycan structures attached to a particular protein. For instance, 
α-fetoprotein (AFP) that is biomarker for detection of liver diseases [60] is not suitable 
for distinguishing between HCC and noncancerous liver diseases in serum levels; 
however, a glycosylated form of AFP, the AFP-L3 fraction, is significantly fucosylated in 
HCC compared to other liver diseases, making it an FDA approved marker for early 
diagnosis of HCC [74]. 
 Developing new technologies and novel glycan analysis techniques has facilitated 
the discovery of many putative glycan-based markers. Because of its sensitivity, 
possibility for high throughput, and tolerance for complex biological samples, mass 
spectrometry is one of the main methods of glycosylation analysis and has increasingly 
been used in cancer biomarkers discovery [75]. In order to detect and measure potential 
cancer markers, biological samples generally need a pre-separation method including 
liquid chromatography (LC), gas chromatography (GC), ion mobility, and capillary 
electrophoresis (CE) before the MS analysis. The common techniques to study 
modifications of glycan structures during development and progression of different types 
of cancer as described in recent reviews are including LC-ESI-MS and MALDI-MS [76], 
[77]. In a study by Kyselova et al. in 2008, it has been shown that N-glycomic profiling of 
serum components using mass spectrometry is a sensitive and informative approach for 
tracking the progression of cancer. Performing a specific MALDI-MS glycomic profile 
analysis on permethylated glycans in sera from breast cancer patients in different stages 
of cancer alongside healthy individuals, they found significant increase in sialylation and 
fucosylation of glycan structures associated with cancer progression [78]. In another 
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study, a chip-based reversed-phase LC-ESI-MS method was applied to reduced and 
permethylated N-glycans extracted from breast cancer samples. In line with other breast 
cancer studies, it was demonstrated that branching and sialylation of glycans increase 
with progression of cancer [79].  
 In 2011, Arnold et al. applied a high-throughput HILIC technology on serum 
samples donated by 100 lung cancer patients (20 samples in each stage I, II, IIIA, IIIB, 
and IV) as well as 84 age-matched controls. Significant increases in levels of SLex, mono-
antennary, and trisialylated glycans were detected in lung cancer samples compared to 
controls. The combination of these significantly increased glycans resulted in higher 
sensitivity and specificity. In addition, the N-glycan profile of whole serum glycome was 
compared to that of isolated haptoglobin and they both had similar glycosylation 
alteration patterns [80].  
 The levels of glycosylation of glycoproteins of bladder cancer cell lines were 
examined by MALDI-TOF/TOF-MS. As a result, SLex, terminal GalNAc and Gal, and 
high mannose-type N-glycans showed significant increases in bladder cancer cells and 
tissues. Furthermore, the expression of core-fucosylated N-glycans were higher in 
bladder cancer cells but that of terminally fucosylated N-glycans were lower [81]. 
 Glycosylation changes were assessed in ovarian cancer using HPLC glycomic 
profiling with fluorescence detection and MS. The levels of core fucosylated, agalactosyl 
biantennary glycans (FA2) and SLex were significantly increased in ovarian cancer 
patients. In this study, they showed that the level of SLex was elevated in the acute-phase 
proteins, haptoglobin, α1-acid glycoprotein, and α1-antichymotrypsin compared to 
healthy controls. In addition, the immunoglobulin G (IgG) contained significantly higher 
level of FA2 [82]. Other studies [83], [84] are in agreement with the results of this study, 
which suggest the independence of abnormal glycosylation from the analytical method. 
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 In a pancreatic cancer study, after purifying and analyzing haptoglobin using LC-
ESI-MS and MALDI-TOF, it was indicated that α1,3-, α1,4-, and α1,6- fucosylation of this 
protein was significantly high among pancreatic cancer patients [85]. In another study in 
2011, Lin et al. identified a bifucosylated triantennary structure for the first time in 
pancreatic cancer samples by extracting haptoglobin from serum, permethylating the 
desialylated N-glycans, and analyzing them by MALDI-QIT-TOF-MS. Comparing the 
results of this analysis applied on sera from 16 pancreatic cancer patients and 15 
individuals with benign conditions, they found higher level of both core and antennary 
fucosylation in pancreatic cancer samples [86]. However, the sample size in this study is 
small and the results have not been validated yet. 
 N-glycans derived from blood serum of 24 prostate cancer patients and 10 
healthy individuals were permethylated and analyzed by MALDI-MS. A total of 12 glycan 
structures were found to be significantly different between cases and controls. Half of 
these glycans were fucosylated. The levels of high mannose and complex biantennary 
structures were lower in cancer patients but fucosylated complex biantennary and 
complex tetraantennary structures were increased in prostate cancer compared to 
controls [87]. 
 The development of new technologies and methods of separation and mass 
spectrometry has led to many studies conducted by different groups to demonstrate the 
correlation of abnormal production of glycans to cancer development and progression. 
All the methods described here analyzed the intact structure of glycans. We recently 
developed a molecularly bottom-up approach to plasma/serum (P/S) glycomics based on 
glycan linkage analysis that captures features such as α2-6 sialylation, β1-6 branching, 
and core fucosylation as single analytical signals [88].  In Chapter 2 of this dissertation, 
validation of robustness of this method is discussed. In chapters 3 and 4, this method 
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was applied to over 1000 P/S samples from patients with different types of cancer across 
all stages matched with certifiably healthy, nominally healthy and/or risk-matched 
controls to evaluate the diagnostic and prognostic capacity of glycan “nodes” in different 
types of cancer.  
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Figure 1.1. Common types of glycans in mammals. Glycans are found covalently 
attached to many different proteins and lipids and are ubiquitously displayed on the 
exterior surfaces of cells. N-glycans that are attached to Asp residue of proteins, have a 
common core that is shown in a dotted line box in the figure. O-glycans that are attached 
to Ser/Thr residue of proteins can have various cores. Glycosaminoglycans are 
unbranched co-polymers consisting of repeating acidic disaccharide units that are 
usually attached to proteoglycans. Glycosphingolipids are a subtype of glycolipids that 
are found on the cell membrane. Glycosylphosphatidylinositol (GPI)-anchored proteins 
are glycoproteins attached to a phosphatidylinositol found on the cell plasma membrane. 
Adopted with permission from Pinho et al. [89].  
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Figure 1.2. General categories of the biological functions of glycans. Endogenous 
recognition is shown by on the left side of the central “self” cell. The right side binding 
demonstrates exogenous recognition. Molecular mimicry of host glycans makes the roles 
of glycans more complicated. In some cases some overlap can be found between different 
categories. Adapted with permission from Varki [1]. 
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CHAPTER 2 
GLYCAN NODE ANALYSIS: VALIDATION OF ASSAY ROBUSTNESS 1 
2.1 Introduction 
Serum glycan composition and structure are well known to be altered in many different 
types of cancer [77], [90]–[92].  In fact, for over a decade now, global blood 
plasma/serum (P/S) glycomics has held out the promise of new, non-invasive cancer 
markers derived from a small volume of this easily accessible biofluid [93], [94]. Modern 
analytical methods for quantifying the relative abundance of different glycans in P/S 
vary widely [95]–[97], ranging from multiplexed capillary gel electrophoresis with laser-
induced fluorescence (a DNA sequencer-adapted method) [98], [99] to hydrophilic 
interaction liquid chromatography (HILIC) [100] or porous graphitized carbon (PGC) 
[101], [102] chromatography interfaced with electrospray ionization-based mass 
spectrometers or as a means of prefractionation prior to analysis by MALDI-MS [103]—
for which glycans are generally permethylated prior to analysis [97], [104]. 
Nearly all approaches employed in P/S glycomics focus on the analysis of intact 
glycans—most commonly N-linked glycans (generally to the exclusion of O-linked 
glycans and glycolipids). Quite commonly, accounts of such studies that are focused on 
cancer conclude by taking a wide-angle view of all intact glycans that were altered in 
cancer relative to a healthy or benign disease state and reporting unique glycan features 
such as core fucosylation, bisecting N-acetylglucosamine (GlcNAc), and α2-6 sialylation 
that were found increased or decreased in cancer [94]. Often these features are then 
directly connected to the activity of specific glycosyltransferases [105]. In 2013, Borges et 
al [88] developed a molecularly bottom-up approach to serum glycomics which, 
following permethylation of an unfractionated P/S sample, employs the principles of 
                                                        
1 This chapter is partially reprinted with permission from S. Ferdosi et al., “Stage Dependence, Cell-Origin Independence, 
and Prognostic Capacity of Serum Glycan Fucosylation, β1–4 Branching, β1–6 Branching, and α2–6 Sialylation in 
Cancer,” J. Proteome Res., p. acs.jproteome.7b00672, 2018. Copyright 2018, American Chemical Society 
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glycan linkage analysis to break down all P/S glycans into monosaccharides in a way that 
maintains information about which hydroxyl groups of each monosaccharide were 
connected to other carbohydrate residues in the original glycan polymer [88], [106], 
[107] (Figures 2.1 and 2.2). This mode of P/S sample preparation results in a 
collection of roughly two dozen partially methylated alditol acetates (PMAAs), each of 
which represents a unique glycan “node” from the original glycan polymers and can 
readily be quantified by GC-MS.  Uniquely, several PMAAs such as those arising from 
2,6-linked mannose, 4,6-linked GlcNAc, and 3,4,6-linked mannose correspond to unique 
glycan features such as β1-6 branching, core fucosylation, and bisecting GlcNAc, 
respectively, and capture these unique features as single analytical signals rather than 
allowing the signal from that feature to be spread across all intact glycans that bear the 
unique feature (Figure 2.1).  Similarly, many of the PMAAs serve as excellent 
surrogates for the activities of the glycosyltransferases (GTs) that produced them—as 
only one or two known human GTs are capable of producing that particular glycan 
monosaccharide linkage pattern [88].  In addition, this unique approach to P/S 
glycomics simultaneously captures information from all major classes of P/S glycans, 
including N-, O-, and lipid-linked glycans [88]. 
Initial analytical validation of this methodology was done previously [88]. In 
order to further validate the robustness of this assay, the glycan “node” analysis 
procedure was applied to matched sets of P/S samples consisting of serum samples and 
plasmas with different types of anticoagulants to determine whether subtle differences in 
sample matrix (i.e., different anticoagulants and serum) have an impact on the glycan 
node composition of the samples. In addition, in order to test the stability of glycans in 
various sample handling conditions, glycan nodes were analyzed in different types of 
samples that were treated in different conditions over a year and their matched controls. 
  22 
2.2 Materials and Methods 
2.2.1 Materials  
Heavy, stable-isotope-labeled D-glucose (U-13C6, 99%; 1,2,3,4,5,6,6-D7, 97%−98%) was 
purchased from Cambridge Isotope Laboratories. N-acetyl-D-[UL-13C6]glucosamine was 
obtained from Omicron Biochemicals, Inc. Methanol was purchased from Honeywell 
Burdick & Jackson. Acetone was obtained from Avantor Performance Materials. 
Acetonitrile and dichloromethane were acquired from Fisher Scientific. Chloroform, 
sodium hydroxide beads (20–40 mesh) DMSO, iodomethane (99%, Cat. No. I8507), 
trifluoroacetic acid (TFA), ammonium hydroxide, sodium borohydride, and acetic 
anhydride were obtained from Sigma-Aldrich. Pierce spin columns (0.9 mL volume) 
including plugs were purchased from ThermoFisher Scientific (Waltham, MA, Cat. No. 
69705). GC-MS autosampler vials and Teflon-lined pierceable caps were acquired from 
ThermoFisher Scientific. GC consumables were purchased from Agilent; MS 
consumables were obtained from Waters. 
 
2.2.2 Plasma and Serum Samples 
The first matched set of P/S samples was including samples from 21 healthy donors. This 
set consisted of four different types of plasma and a serum sample from each donor. The 
difference between these four types of plasma was based on the different anticoagulants, 
which were K2EDTA, K3EDTA, Sodium EDTA, and 3.8% Sodium Citrate. The second 
matched set of P/S samples was including 6 matched-collection aliquots of serum, 
K2EDTA plasma, and heparin plasma from a single donor. In each matched set, samples 
were analyzed and compared to each other to verify the consistency of glycan nodes 
between the aforementioned types of samples. 
  23 
In order to test the stability of glycans in various sample handling conditions, 7 
different types of samples were treated in different conditions over a year. By the end of 
360 day time point, glycan nodes were analyzed in these treated samples and their 
matched controls that were stored at -80 °C the whole time. The samples were including 
2 male and 2 female Na2EDTA plasmas that were matched to serum, K2EDTA and 
Heparin plasma from a separate male donor. The different mistreating conditions were 
including 10 days at -20 °C, 90 days at -20 °C, 360 days at -20 °C, 2 days at 4 °C, 90 days 
at 4 °C, and 1 day at 25 °C. 
 All specimens were stored at -80 °C prior to shipment to ASU and maintained at -
80 °C at ASU prior to analysis (except for the ones that were intentionally mistreated for 
the stability test). All specimens were analyzed blind and in random order. An aliquot of 
plasma from the same individual donor was analyzed in every batch as a quality control 
(QC) specimen to ensure batch-to-batch consistency. 
 
2.2.3 Experimental Procedures: Glycan Node Analysis 
The global glycan methylation analysis procedure consisted of four main steps; 
permethylation, trifluroacetic acid (TFA) hydrolysis, reduction of sugar aldehydes, 
acetylation of nascent hydroxyl groups and final cleanup [88], [106]. Each step is 
described in detail below. 
Permethylation, Non-reductive Release, and Purification of Glycans: A total of 9 
µL of P/S was added into a 1.5 mL eppendorf tube followed by 1 µL of a 10 mM solution 
of heavy-labeled D-glucose (U-13C6, 99%; 1,2,3,4,5,6,6-D7, 97%−98%), and N-acetyl-D-
[UL-13C6]glucosamine which served as internal standards for relative quantification. 
Then, 270 µL of dimethylsulfoxide (DMSO) was added to the biological sample and 
mixed to dissolve completely. Once the sample was fully dissolved, 105 µL of 
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iodomethane was added to the mixture. This solution was then added to a plugged 1 mL 
spin column, which contained ~ 0.7 g of sodium hydroxide beads. The NaOH beads had 
been preconditioned with acetonitrile, and rinsed with DMSO twice before the sample 
was added. Then, the NaOH column was stirred occasionally for 11 min. When finished, 
samples were unplugged and spun for 15 s at 5,000 rpm (2,400g) in a microcentrifuge to 
extract the glycan-containing solution. To wash off all the permethylated glycan, 300 µL 
of acetonitrile was added to the spin column and then centrifuged for 30 s at 10,000 rpm 
(9,600g). Then, samples from the first spin-through were placed in a silanized 13 × 100 
mm glass test tube containing approximately 3.5 mL of 0.5 M NaCl solution in 0.2 M 
sodium phosphate buffer and mixed well. Next, the second spin-through was pooled with 
the rest of the sample, avoiding the white residue at the bottom of the spin column. The 
test tube was capped and shaken thoroughly after adding 1.2 mL of chloroform to the 
sample. Liquid/liquid extraction was performed 3 times, saving the chloroform layer. 
The chloroform layer was then extracted with a silanized pipette, transferred to a 
silanized glass test tube, and dried under nitrogen at heater-block temperature setting of 
74 °C. 
TFA hydrolysis: A total of 325 µL of 2 M TFA was added to each sample. Samples 
were then capped and heated at 121 °C for 2 h. Afterward, samples were dried down 
under nitrogen at 74 °C. 
Reduction of Sugar Aldehydes: A total of 475 µL of a freshly prepared 10 mg/mL 
solution of sodium borohydride in 1 M ammonium hydroxide was added to each test 
tube. After letting the sample react for 1 h at room temperature, 63 µL of methanol was 
added to each sample, then dried down at 74 °C under nitrogen. A solution of 9:1 (v/v) 
methanol: acetic acid was then prepared and 125 µL was added to each test tube, which 
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was again dried under nitrogen. Before moving forward, the samples were fully dried in 
vacuum desiccator for at least 15-20 min. 
Acetylation of Nascent Hydroxyl Groups: A total of 18 µL of water was added to 
each sample and mixed well to dissolve the entire sample residue. A total of 250 µL of 
acetic anhydride was then added to each sample. Next, the sample was sonicated in a 
water bath for 2 min followed by an incubation for 10 min at 60 °C. 230 µL of 
concentrated TFA was then added to each test tube. The capped test tube was then 
incubated at 60°C for 10 min. 
Final Cleanup: Approximately 2 mL methylene chloride was added to each test 
tube and mixed well.  Then, 2 mL water was added to each sample and mixed well. 
Liquid/liquid extraction was performed twice, saving the organic layer. Next, the organic 
layer was transferred with a silanized glass pipette into a silanized autosampler vial. The 
organic layer was then evaporated under nitrogen, reconstituted in 120 µL of acetone 
and capped for injection onto GC-MS. A molecular overview of the global glycan 
methylation analysis procedure is shown in Figure 2.2. 
Gas Chromatography-Mass Spectrometry: For sample analysis, an Agilent Model 
A7890 gas chromatograph (equipped with a CTC PAL autosampler) was used coupled to 
a Waters GCT (time-of-flight) mass spectrometer. A total of 1 µL of the sample was 
injected in split mode onto an Agilent split-mode liner that contained a small plug of 
silanized glass wool with the temperature set to 280 °C. For all samples, one injection 
was made at split ratio of 20:1. A 30-m DB-5 ms GC column was used for 
chromatography. The oven temperature was initially held at 165 °C for 0.5 min. Then, 
the temperature increased 10 °C/min up to 265 °C, followed by immediate increase of 30 
°C/min to 325 °C where it was kept constant for 3min. Total run time was 15.5 min. The 
temperature of the transfer line was kept at 250 °C. After the sample components were 
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eluted from the GC column, they were subjected to electron ionization with an electron 
energy of 70 eV at a temperature of 250 °C. The m/z range of analysis was 40-800 with a 
scan cycle time of 0.1 s. Perfluorotributylamine was used for daily tuning and calibration 
of the mass spectrometer. 
 
2.2.4 Data Processing  
Quantification was done by integrating the summed extracted ion chromatogram peak 
areas (details provided elsewhere [88]), using QuanLynx software. The peaks were 
integrated automatically and verified manually. Then, all the information given by 
integration was exported to a spreadsheet for further analysis. 
 
2.2.5 Statistical Analysis 
The peak areas for individual hexoses were normalized to sum of all the endogenous 
hexoses and those of individual HexNAcs were normalized to sum of all endogenous 
HexNAcs. For the stability test, beside this normalization method, the peak areas for 
individual hexoses were normalized to heavy glucose and those of individual HexNAcs 
were normalized to heavy N-acetyl glucosamine (heavy GlcNAc). Differences between 
different sample matrices as well as different sample handling conditions were evaluated 
by means of the Friedman test followed by Dunn’s post hoc test using GraphPad Prism 7. 
 
2.3 Results and Discussion 
2.3.1 Glycan Node measurements in Different Sample Matrices  
Only a few statistically significant differences between the P/S matrices were observed 
(Tables 2.1 and 2.2). Based on these results, sodium citrate and sodium EDTA plasma 
samples, which account for all of the pair-wise differences observed in Table 2.1, were 
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excluded from clinical studies involving “glycan node analysis”. A few remaining 
differences (noted within the smaller sample set involving heparin plasma; Table 2.2), 
while statistically significant, were small and actually within the interassay precision 
range for the relevant markers [106]. 
 
2.3.2 Stability of Glycan Nodes in Different Conditions 
No statistically significant difference was observed between the samples handled in 
conditions other than -80 °C and controls. Comparing glycans in only the EDTA plasma 
samples (excluding serum and Heparin plasma) at different conditions to the controls 
resulted in one slightly significant difference in 6-linked galactose between samples 
stored at 25 °C for 1 day and their controls (Table 2.3), which is within the interassay 
precision range for this marker [106]. 
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Figure 2.1. Conceptual overview of the glycan “node” analysis concept—which 
essentially consists of applying glycan linkage (methylation) analysis to whole biofluids. 
Intact normal and abnormal glycans including O-glycans, N-glycans and glycolipids, are 
processed and transformed into partially methylated alditol acetates (PMAAs, Fig. 2.2), 
each of which corresponds to a particular monosaccharide-and-linkage-specific glycan 
“node” in the original polymer. As illustrated, analytically pooling together the glycan 
nodes from amongst all the aberrant intact glycan structures provides a more direct 
surrogate measurement of abnormal glycosyltransferase activity than any individual 
intact glycan, while simultaneously converting unique glycan features such as “core 
fucosylation”, “α2-6 sialylation”, “bisecting GlcNAc”, and “β1-6 branching” into single 
analytical signals. Actual extracted ion chromatograms from 9-µL blood plasma samples 
are shown. Numbers adjacent to monosaccharide residues in glycan structures indicate 
the position at which the higher residue is linked to the lower residue. Figure adapted 
with permission from Borges CR et al. Anal. Chem. 2013, 85(5):2927-2936. Copyright 
2013 American Chemical Society. 
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Figure 2.2. Molecular overview of the glycan “node” analysis procedure. For glycans 
from blood plasma and other biofluids, O-linked glycans are released during 
permethylation, while N-linked glycans and glycolipids are released during acid 
hydrolysis. The unique pattern of methylation and acetylation in the final partially 
methylated alditol acetates (PMAAs) corresponds to the unique “glycan node” in the 
original glycan polymer and provides the molecular basis for separation and 
quantification by GC-MS. Figure adapted with permission from Borges CR et al. Anal. 
Chem. 2013, 85(5):2927-2936. Copyright 2013 American Chemical Society. 
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Table 2.1. Impact of plasma and serum matrices on glycan node 
measurements. Data were acquired from 21 healthy individuals from which 5 different 
plasma or serum matrices were collected at the same draw. Differences between matrices 
were evaluated by the Friedman test followed by Dunn’s post hoc test; p > 0.05 (ns), p < 
0.05 (*), p < 0.01 (**). 
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Table 2.2. Comparison of sodium heparin plasma to potassium EDTA 
plasma and serum matrices.  Data were acquired from 6 replicate analyses (per 
matrix) of a matched set of samples taken from a single donor during one blood draw. 
Differences between matrices were evaluated by the Friedman test followed by Dunn’s 
post hoc test; p > 0.05 (ns), p < 0.05 (*). 
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Table 2.3. Comparison of glycan node stability at different conditions to 
controls stored at -80 °C. Hexose data were normalized to heavy, stable isotope 
labeled glucose (Glc) and HexNAc data normalized to heavy, stable isotope labeled 
GlcNAc. Differences between time points were evaluated by Friedman test followed by 
Dunn’s post hoc test; p > 0.05 (ns), p < 0.05 (*). 
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CHAPTER 3 
STAGE DEPENDENCE, CELL-ORIGIN INDEPENDENCE, AND PROGNOSTIC 
CAPACITY OF SERUM GLYCAN FUCOSYLATION, β1-4 BRANCHING, β1-6 
BRANCHING AND α2-6 SIALYLATION IN CANCER 2 
3.1 Introduction 
To date, we have only reported results from pilot studies in which our molecularly 
bottom-up glycomics methodology known as “glycan nodes analysis” was applied to 
(mostly) advanced stages of lung [88] and breast cancer [107]. In order to gain a 
representative perspective on the potential utility of this approach to detecting a variety 
of different types of cancer at varying stages, we have now applied it to over 950 clinical 
P/S samples from 7 different case control studies across all stages of cancer in which the 
cancer cases were compared to related benign conditions and/or healthy controls. A 
study of plasma samples from 428 Stage I-IV lung cancer patients, age/gender/smoking-
status matched controls, and certifiably healthy living kidney donors served as the 
backbone for this report—in which plasma from a single donor served as a quality 
control specimen in every single batch of samples—facilitating comparisons to pancreatic 
(rapid autopsy), ovarian (Stage III), prostate (Stage II), and a large independent lung 
cancer (Stage I) case-control study.  Based on the behavior of P/S glycans established to 
date, we hypothesized that the alteration of P/S glycans observed in cancer would be 
independent of the tissue in which the tumor originated yet exhibit stage dependence 
that varied little across cancers classified on the basis of tumor origin. 
 
 
 
                                                        
2 Reprinted with permission from S. Ferdosi et al., “Stage Dependence, Cell-Origin Independence, and Prognostic 
Capacity of Serum Glycan Fucosylation, β1–4 Branching, β1–6 Branching, and α2–6 Sialylation in Cancer,” J. Proteome 
Res., p. acs.jproteome.7b00672, 2018. Copyright 2018, American Chemical Society. 
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3.2 Materials and Methods 
3.2.1 Materials  
Materials for glycan node analysis are listed in section 2.2.1. Glucose colorimetric assay 
kit was obtained from Cayman Chemical (Cat. No. 10009582). 
 
3.2.2 Plasma and Serum Samples 
A summary of the case-control sample sets employed in this study is provided in Table 
3.1. All specimens were collected in compliance with the Declaration of Helsinki 
principles. Once collected they were coded and de-identified to protect patient identities. 
Living Kidney Donors: EDTA plasma samples from certifiably healthy living 
kidney donors were enrolled in the Multidisciplinary Biobank at Mayo Clinic Arizona 
under a Mayo Clinic IRB approved protocol. Patients eligible for enrollment were those 
seen at Mayo Clinic Arizona who were ≥ 18 years old, able to provide informed consent, 
and undergoing evaluation as a potential living kidney donor.  Detailed inclusion & 
exclusion criteria for these patients are provided in Appendix A.  None of these patients 
smoked at the time of health screening and blood collection, 27% were former smokers 
and 73% never smoked. Specimens were collected over a 2-year period from Dec. 2013 to 
Dec. 2015. Standard operating protocols and blood collections were performed as 
previously described [108]. All specimens were stored at -80 °C prior to shipment to 
ASU. 
Large Lung Cancer Set: Sodium heparin plasma samples for the large lung cancer 
study were collected at the University of Texas MD Anderson Cancer Center under the 
supervision of Dr. Xifeng Wu. Heparin is a glycosaminoglycan itself but the vast majority 
of its monomer units are carboxylated and/or sulfated.  As we have previously described 
[88], sulfated and carboxylated glycan monomers cannot be detected by the analytical 
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methodology employed in this study. The PMAA from 4-linked GlcNAc could 
theoretically be produced by the heparin anticoagulant, but empirically we found in our 
matched collection studies (described in Chapter 2) that 4-linked GlcNAc from heparin 
plasma is not significantly different from EDTA plasma or serum. Specimens for lung 
cancer cases and controls from the University of Texas MD Anderson Cancer Center 
included in this study are part of an ongoing large lung cancer study that has been 
recruiting since 1995.  This study has received approval from the University of Texas MD 
Anderson Cancer Center and Kelsey-Seybold institutional review boards.  Venous blood 
was drawn from newly-diagnosed and histologically confirmed lung cancer patients 
(prior to therapy) and age/gender/ethnicity-matched controls at the MD Anderson 
Cancer Center hospital and the nearby Kelsey Seybold Clinic, respectively.  All blood was 
drawn and processed under the same SOP.  Patients were not necessarily in a fasted 
state. Blood was centrifuged then aliquoted and placed into a liquid nitrogen tank.  After 
collection samples were coded and de-identified prior to shipment to Arizona State 
University for analysis. A more detailed profile of the clinical characteristics of the 
patients in this large lung cancer study is provided in Table 3.2. 
Liver Fibrosis (Non-Cancerous): Serum samples from patients at all stages of 
liver fibrosis were collected at the Sunnybrook Health Sciences Centre, under the 
direction of Dr. Lei Fu and Dr. David E. C. Cole. This study was approved by Research 
Ethics Board, Sunnybrook Health Sciences Centre, Toronto. Patients were recruited 
between 2007 and 2011. Written informed consent was obtained from each participant. 
All subjects with various chronic liver diseases were considered eligible if they would 
have liver biopsy for the diagnosis of liver fibrosis as part of their routine care. Blood 
specimens were collected and serum was separated from cells following standard clinical 
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laboratory procedures. Serum aliquots were stored in -70 °C. The specimens were coded 
and de-identified according to the study protocol. 
Stage I Lung Adenocarcinoma: Serum samples from stage I lung adenocarcinoma 
patients and age/gender/smoking-status matched controls were collected under NYU 
Institutional Review Board (IRB) approval at the NYU Langone Medical Center by Dr. 
Harvey Pass. Arterial blood samples were collected from fasting patients undergoing 
surgery in the time frame from September 2006 to August 2013 to remove one or more 
lung nodules that were detected during a CT scan.  Determination of whether nodules 
were benign or malignant was made following a pathological exam of the excised 
nodules. Serum was collected in standard glass serum tubes and allowed to sit upright 
for 30-60 minutes to allow clotting. Subsequently, tubes were centrifuged at 1,200 x g for 
20 min at room temperature, then aliquoted and placed at -80 °C within 2-3 hours of 
collection. No freeze-thaw cycles occurred prior to shipment to Arizona State University 
(Borges lab) for analysis. 
The original set of serum samples for analyzing stage I lung adenocarcinoma 
were including cases that were arterial blood samples collected from fasting patients 
during surgery by Dr. Harvey Pass. The age, gender, and smoking-matched controls were 
venous blood samples collected from patients during doctor visit by Dr. Bill Rom. This 
set of samples was excluded from this study because of the reasons explained in the 
Discussion section. 
Stage II Prostate Cancer: Serum samples from stage II prostate cancer patients 
were obtained from the Cooperative Human Tissue Network (CHTN)—an NIH-
sponsored biospecimen collection agency. The quality management system of the CHTN 
is described elsewhere [109]. Age-matched control samples from nominally healthy male 
donors were obtained from ProMedDx (Norton, MA). 
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Stage III Serous Ovarian Cancer: Serum specimens from stage III serous ovarian 
cancer patients were collected at Brigham and Women’s Hospital under IRB approval by 
Dr. Daniel Cramer. Sera were obtained at the time of presentation prior to surgery. Age, 
gender, and location matched control sera from women without a history of cancer 
(other than non-melanoma skin cancer) were obtained from the general population 
under a standardized serum collection protocol. All serum samples were collected from 
2001 to 2010 and were stored at -80 °C prior to analysis. These specimens have 
previously been described [110], [111].  
Stage IV Lung Cancer: A set of serum samples from stage IV lung cancer patients 
and age/gender matched nominally healthy control donors that was completely separate 
from those provided by Dr. Xifeng Wu at the University of Texas MD Anderson Cancer 
Center was obtained from ProMedDx. 
Rapid Autopsy Pancreatic Cancer: Serum specimens from rapid autopsy patients 
who had recently died from pancreatic cancer were collected by Dr. Michael 
Hollingsworth at the University of Nebraska Medical Center under IRB approval. These 
samples have previously been described [112]. In brief, specimens were collected within 
2-3 hrs of death. Control serum samples were from patients with benign pancreatic 
conditions and elevated CA19-9 levels. Samples were coded, de-identified and kept at -
80 °C prior to shipment to ASU. 
Additional Biospecimen Details: As described above, all blood samples were 
processed into P/S immediately following collection and stored at -70 °C or colder until 
analyzed. Following shipment in dry ice, vial headspace was vented prior to thawing to 
avoid CO2-mediated sample acidification [113]. The molecular integrity of the sample set 
that showed the greatest differences between cases and controls (rapid autopsy 
pancreatic cancer sera) was examined using an assay based on ex vivo protein oxidation 
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that was recently developed by the Borges group [114]. The prostate cancer and stage I 
lung adenocarcinoma sets were spot-checked as well. No samples produced evidence for 
concern about specimen integrity.     
In this study, multiple independent sets of sample were compared to each other. 
Each case-control set was analyzed blind and in random order. Within each batch, across 
all sets, a quality control (QC) EDTA plasma sample was included consisting of a 9-uL 
aliquot of the same bulk plasma sample in order to verify the reproducibility across 
batches.  Notably, the samples from the certifiably healthy living kidney donors were 
analyzed in separate batches of samples from those in the large lung cancer set. To justify 
direct comparison of these two sets of samples, we verified that the average values 
measured for each glycan node in the two sets of QC sample results were not statistically 
significantly different. Moreover, if the average value of the QC sample was slightly 
higher or lower in the large lung cancer set relative to the living kidney donor set a 
scaling factor based on this difference in QC samples was employed to adjust the living 
kidney donor data set. For each glycan node, this adjustment brought the living kidney 
donor data set distribution slightly closer to the control distributions observed in the 
large lung cancer set—meaning that it was a conservative adjustment. 
 
3.2.3 Experimental Procedures 
3.2.3.1 Glycan Node Analysis 
The experimental procedure and data processing for glycan node analysis are described 
in details in sections 2.2.3 and 2.2.4, respectively. 
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3.2.3.2 Glucose Oxidase-Based Assay 
Glucose colorimetric assay kit was used for measuring the concentration of glucose in 
serum samples. A total of 10 mL of 250 mM sodium phosphate assay buffer was diluted 
with 40 mL of HPLC-grade water in order to be used for dilution of glucose standards 
and enzyme mixture. To prepare standard solutions a 100 mg/dL stock solution was 
made using 50 µL of the 1000 mg/dL glucose standard and 450 µL of diluted assay 
buffer. Using the stock solution, glucose standards with concentrations of 0, 2.5, 5, 7.5, 
10, 15, 20, and 25 mg/dL were made. To perform the assay, 15 µL of each standard and 
sample was added to two wells followed by 85 µL of diluted assay buffer. By adding 100 
µL of enzyme mixture, which was reconstituted with 6 mL of diluted assay buffer, the 
reaction was initiated. Then, the plate was covered with the plate cover and incubated for 
10 min at 37 °C. The plate cover was then removed and the absorbance was read at 500-
520 nm using a Thermo Scientific Multiskan Go plate reader. The concentrations of 
glucose in the samples were calculated using SkanIt Software 3.2. 
 
3.2.4 Statistical Analysis 
The peak area for each glycan node was normalized in one of two possible ways: In the 
first approach, individual hexoses were normalized to heavy glucose and individual 
HexNAcs were normalized to heavy N-acetyl glucosamine (heavy GlcNAc). (Notably, 
these two internal standards were omitted during analysis of the prostate cancer set of 
samples.) In the second approach, individual hexoses were normalized to the sum of all 
endogenous hexoses and individual HexNAcs were normalized to the sum of all 
endogenous HexNAcs. This normalization scheme provided modestly improved within-
batch reproducibility, but limited observation of potential simultaneous increases in all 
glycan nodes. Each stage of each cohort was log-transformed and outliers were removed 
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with the ROUT method at Q = 1% using GraphPad Prism 7.  Data were then reversed 
transformed by taking the anti-log of each value. Differences between patient cohorts 
and stages in the large lung cancer study were evaluated by means of the Kruskal-Wallis 
test followed by the Benjamini-Hochberg false discovery correction procedure using R 
version 3.3.3. This software was also used to generate and plot receiver operating 
characteristic (ROC) curves.  ROC curves were compared via DeLong’s test using 
RStudio Version 1.0.143. Stage-by-stage multivariate modeling on the large lung cancer 
set was carried out using multivariate logistic regression, with performance assessed by 
leave-one-out cross-validation, and model selection carried out using a best subsets 
procedure.  These analyses were carried out using R version 3.3.3.  The ability of 
particular glycan nodes to predict cancer progression and survival was assessed via Cox 
proportional hazards regression models using XLSTAT Version 2012.3.01—the results of 
which were verified (duplicated) using SAS 9.4. Survival curves were generated and 
associated log-rank Mantel-Cox tests were carried out using GraphPad Prism 7. 
 
3.3 Results 
The primary focus of this study was the large lung cancer set as it constituted the single 
largest set and covered all stages of cancer. A summary of all sample sets analyzed as 
part of this study is provided in Table 3.1. In total, 19 glycan “nodes” were measured 
with relative abundances that were consistently greater than 1% of respective total 
hexoses or total N-acetylhexosamines (HexNAcs). As reported elsewhere, this threshold 
ensures quantitative precision between batches of samples [88], [106]. Relative to the 
age/gender/smoking-status matched controls, significant changes were observed in 4 
out of 19, 2 out of 19, 17 out of 19 and 17 out of 19 nodes in plasma samples taken from 
stage I, II, III and IV patients, respectively (Table 3.3). Based on normalization to 
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heavy, stable isotope-labeled glucose and GlcNAc internal standards, all altered glycan 
nodes except 4-Glc (which is mostly derived from glycolipids) were elevated in the cancer 
patients relative to the controls. Analogous results for data in which each hexose was 
normalized to the sum of endogenous hexoses and each HexNAc was normalized to the 
sum of endogenous HexNAcs revealed that this alternate normalization procedure is not 
as effective at teasing out differences between the cohorts in the large lung cancer study 
(Table 3.4).  
 
3.3.1 Highly Altered Glycan Features 
The five glycan nodes that were most elevated in the cancer cases relative to the at-risk 
controls included the following: 1) Terminal fucose—which corresponds to essentially all 
fucose in blood plasma. (Non-terminal fucose is only found in Notch proteins [88], [3] 
which, at most, would contribute only an infinitesimal fraction of the fucose found in 
blood plasma and, if ever detected by the approach employed here, would be observed as 
3-linked fucose.) 2) 6-linked galactose, which corresponds specifically to α2-6 sialylation 
and almost completely to the activity of the ST6GalI glycosyltransferase enzyme [88]; 3) 
2,4-linked mannose, which corresponds to β1-4 branching of N-linked glycans and 
almost completely to the activity of the GnT-IVa enzyme [88]; 4) 2,6-linked mannose, 
which corresponds to β1-6 branching of N-linked glycans and to the activity of the GnT-V 
enzyme [88]; 5) 3,4-linked N-acetylglucosamine (GlcNAc), which predominately 
corresponds to outer-arm fucosylation and the activity of the FucT-III, FucT-V, FucT-VI, 
and FucT-XI enzymes [88]. The univariate distributions of these five glycan nodes 
(normalized to heavy glucose or heavy GlcNAc added as an internal standard), along 
with receiver operating characteristic (ROC) curves that describe the potential clinical 
relevance of their distributions are shown in Figure 3.1. 
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3.3.2 Stage and Health-Status Dependence 
Table 3.3 and Figure 3.1 illustrate both the strong stage-dependence of these glycan 
features as well as the notable contrast of their distributions in certifiably healthy 
individuals compared to the general middle-aged to elderly population (i.e., “controls”) 
who are at a similar risk for cancer as individuals who actually had cancer. Similar 
distributions and trends were noted when the five glycan nodes were normalized to the 
sum of endogenous hexoses or HexNAcs, but the ROC c-statistics (areas under the curve, 
AUCs) tended not to be as large (Figure 3.2). The average age of the certifiably healthy 
living kidney donor population was 47 and that of both the controls and lung cancer 
cases in this set of samples was 61 (Table 3.2). However, after pooling data from the 
certifiably healthy donors, controls and lung cancer cases and correcting for multiple 
comparisons, no statistically significant correlations with age were observed for any of 
these glycan nodes. (Before correcting for multiple comparisons, terminal (total) fucose 
appeared slightly correlated with age (Pearson correlation R2 = 0.013 and p = 0.021), but 
this result cannot be considered statistically significant after considering the fact that 
multiple comparisons were made.) Likewise, no statistically significant correlations of 
glycan nodes with age were observed when these groups of patients were evaluated 
individually. 
In general, the five glycan nodes increased together as the stage of cancer 
advanced (Figure 3.3).  Moreover, the behavior of these nodes was independent of the 
organ of tumor origin, at least when comparing lung cancer with pancreatic, ovarian and 
prostate cancers (Table 3.5). This is evident when panels a, c and d of the left column of 
Figure 3.3 are compared with their respective lung cancer stages shown in the right 
column.  At stage IV both outer-arm fucosylation and terminal (total) fucosylation lag a 
bit behind α2-6 sialylation, β1-4 branching and β1-6 branching—but fucosylation-related 
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nodes caught up and even surpassed these other glycan features once cancer had fully 
run its course (Figure 3.3a).  When stage was held constant, no glycan nodes were 
found to be significantly different between adenocarcinoma, squamous cell carcinoma 
and small cell carcinoma—the three different histological sub-types observed in the large 
lung cancer study (Table 3.2).  However, terminal (total) fucosylation, β1-6 branching, 
and outer-arm fucosylation were altered within the control cohort on the basis of 
smoking status (grouped as never-smokers, former smokers or current smokers; Figure 
3.4). 
Cases and controls in the original set of stage I lung adenocarcinoma patients 
were best separated when data were normalized to terminal glucose (t-Glc) (Figure 
3.5). In order to determine if the source of these differences was blood glucose or the 
glycan nodes, a glucose oxidase-based assay was used to measure the amount of free 
glucose in these serum samples. This glucose assay revealed that the cases had 
significantly higher level of glucose concentration with the average of 92.23 mg/dL 
relative to controls with that of 77.52 mg/dL (Mann Whitney test; p < 0.0001). 
 
3.3.3 Orthogonality of Glycan Features 
In order to evaluate the orthogonality of all 19 glycan nodes included in this study 
(Table 3.3), multivariate logistic regression models were created for the large lung 
cancer set on a stage-by-stage basis (Figure 3.6). Results of modeling are shown as 
ROC curves, where the model-derived predicted probability of disease for the sample 
was used as the discriminatory variable. In summary, the fully cross-validated forms of 
these multivariate logistic regression models do not distinguish lung cancer cases from 
controls any better than individual glycan nodes (cf. Figure 3.3f-i). This indicates a 
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general lack of orthogonality or independence between the glycan features observed in 
this study. 
 
3.3.4 Comparison to Liver Fibrosis 
The vast majority of glycoproteins found in blood P/S are derived from either liver 
glycoproteins or immunoglobulins (IgG molecules) secreted by the immune system [115], 
[116]. Essentially all non-protein targeting serum glycomics approaches, including the 
one employed in this study, detect changes in these glycans and not novel glycans 
secreted or sloughed-off by cancer cells. This concept has been acknowledged elsewhere 
[117].  Nevertheless, P/S glycans are notoriously known for being altered in cancer [77], 
[90]–[92], [118]. However, they are also known to be altered in inflammatory conditions 
in the absence of cancer [119]–[121].  As an initial attempt to begin to parse out the 
behavior of the five glycan nodes that were most elevated in the large lung cancer set, 
they were analyzed in a set of serum samples from liver fibrosis patients (Figure 3.7). 
Statistical analysis (Kruskal-Wallis) indicated that there were no significant differences 
in any of the glycan nodes shown across all stages of liver fibrosis. This may have been 
due to limited statistical power. Notably, however, fucosylation-related markers 
exhibited a tendency to be elevated in stage III-IV liver fibrosis. 
 
3.3.5 Prediction of Progression and All-Cause Mortality 
The five glycan nodes that were most elevated in the large lung cancer set were evaluated 
for their ability to predict both progression and all-cause mortality in a Cox proportional 
hazards regression model. After adjusting for age, gender, smoking status and cancer 
stage, only 6-linked galactose, which corresponds to α2-6 sialylation, predicted both 
progression and all-cause mortality with p-values of < 0.01 when the glycan nodes were 
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modeled as continuous variables.  All four other top-performing glycan nodes were able 
to predict survival (p < 0.05), but only β1-4 branching and β1-6 branching were also able 
to predict progression (p < 0.05).  Because relative rather than absolute quantification 
was employed, glycan node units lack readily interpretable meaning.  As such, 
measurements of α2-6 sialylation were broken into quartiles and the Cox proportional 
hazards analysis repeated.  After adjusting for age, gender, smoking status and cancer 
stage, the top α2-6 sialylation quartile predicted progression with a hazard ratio of 2.45 
relative to all other quartiles combined (lower bound at 95% CL = 1.54; upper bound at 
95% CL = 3.90; p = 1.5 x 10-4). Likewise, after the same adjustments, the top α2-6 
sialylation quartile predicted all-cause mortality with a hazard ratio of 1.52 relative to all 
other quartiles combined (lower bound at 95% CL = 1.02; upper bound at 95% CL = 
2.23; p = 0.042). Progression and survival curves illustrate the differences in the rates of 
occurrence of these events for the top α2-6 sialylation quartile vs. all other quartiles 
(Figure 3.8). Progression and survival curves for stage III patients alone illustrate that 
the separation of progression by α2-6 sialylation and the separation of survival by α2-6 
sialylation is not simply driven by stage (Figure 3.8c-d). The α2-6 sialylation was not 
elevated or able to predict progression or survival in the stage I lung adenocarcinoma set. 
 
3.4 Discussion  
The five glycan features that were most elevated relative to healthy individuals and at-
risk controls were terminal (total) fucosylation, α2-6 sialylation, β1-4 branching, β1-6 
branching and outer-arm fucosylation (Table 3.3 and Figures 3.1 and 3.3). Two 
phenomena stood out most with regard to their distributions amongst the cohorts of the 
large lung cancer study: First, there was a striking stage dependence of all five glycan 
features that was independent of the tumor organ of origin (Table 3.3, Figures 3.1 
  46 
and 3.3, and Table 3.5). In part, statistical significance at earlier stages may not have 
been achieved due to the relatively low number of samples measured from patients at 
stages I-II (n ~ 20 per stage).  Statistically significant elevation of core-branched O-
glycans (i.e., 3,6-linked GalNAc) over age/gender/smoking-status matched controls was 
observed in stage I lung adenocarcinoma from this separate, larger set of samples 
(Figure 3.3).  However, it was clear from the ROC curve (Figure 3.3e) that this glycan 
node cannot serve as a useful early stage diagnostic biomarker. The original set of stage I 
lung adenocarcinoma samples was excluded from this study for two reasons: 1) Since the 
samples from cancer patients were collected during surgery, these patients had a 
significantly higher level of glucose (which was caused by pre-surgical hyperglycemia) 
relative to controls that were collected from patients during doctor visit. This difference 
between the location/setting of blood collection explained the elevated glucose in the 
case samples measured by the glucose oxidase-based assay. 2) After analyzing this set of 
samples, it was disclosed by our collaborators that the controls were exposed to the 
thawed state significantly longer than cases. Although based on the stability test this 
second issue does not have a major impact on glycan node stability, it can be a major 
issue for other analytes. In general, the importance of these two problems could easily be 
reversed, depending on the analyte(s) of interest. The secondary set of stage I lung 
adenocarcinoma, when normalized to the sum of endogenous hexoses or hexNAcs, 
demonstrated similar ROC curves to the original set for the top performing glycan nodes 
(Figure 3.5a,c). However, when normalized by t-Glc, they are significantly different 
(Figure 3.5b,d). The separation of cases and controls in the original set of stage I lung 
adenocarcinoma is caused by the elevated levels of glucose in cancer patients, which is 
not clinically valuable. 
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A second notable feature apparent in the large lung cancer set was the statistically 
significant difference between certifiably healthy living kidney donors and risk-matched 
controls for α2-6 sialylation, β1-4 branching and β1-6 branching—with controls always 
increased toward the direction of cancer (Table 3.3 and Figure 3.1). These differences 
between certifiably healthy individuals and patients with an elevated risk of cancer 
underscore the high risk of false discovery when nominally healthy sample donors rather 
than well-characterized, clinically relevant controls are employed during biomarker 
development.  The notable differences between healthy individuals and at-risk controls 
also supports the idea that the biological landscape within plasma/serum may undergo 
“grooming”, “conditioning” or pre-metastatic “niche” formation prior to cancer taking 
hold within the body [122]–[126]. Given that inflammation is closely tied to the 
development of cancer [127], [128] and that at least some glycans and glycan features are 
known to be altered in inflammatory conditions in the absence of cancer [119]–[121], 
pre-cancerous inflammation may be responsible for the elevation of many of the glycan 
features observed in the at-risk controls relative to the certifiably healthy living kidney 
donors—suggesting that the goal of preventing such a pre-cancerous state may be as 
important as preventing the transition from an at-risk state to stage I cancer. With this in 
mind, it is interesting to note that about 62% of the age-qualified U.S. population would 
be excluded as living kidney donors due to preventable health conditions. 
A few studies have been published that are closely related to the one reported 
here, but in which intact glycans were analyzed [80], [117], [129].  While not in conflict 
with any of these studies, our most prominent findings of increased terminal (total) 
fucosylation, α2-6 sialylation, β1-4 branching, β1-6 branching and outer-arm 
fucosylation in stage III-IV lung cancer are most closely aligned with the major changes 
reported by Vasseur et al [117] for intact glycans in lung cancer.  They reported 
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significant increases in fucosylated tri- and tetra-antennary structures, outer-arm 
fucosylated structures, and α2-6 sialylated structures. Moreover, they reported that all of 
these features were elevated in control-group former smokers relative to control group 
non-smokers. We found increases in terminal (total) fucosylation, β1-6 branching and 
outer-arm fucosylation in current smokers relative to never smokers, but only increases 
in terminal (total) fucosylation and outer-arm fucosylation in former smokers relative to 
never smokers (Figure 3.4). Notably, the methods employed for the analysis of intact 
glycans by Vasseur et al is one of just a few approaches that are capable of distinguishing 
6-linked from 3-linked sialic acid [130]–[132].  
Multivariate logistic regression models were not able to outperform individual 
glycan nodes (cf Figure 3.3f-i and Figure 3.6) with regard to distinguishing cancer at 
stages I-IV from controls. This indicates a general lack of biological orthogonality 
amongst the abnormal glycan features observed—suggesting that they likely have a 
singular (or small set of closely related) upstream causes: The concentration of 
glycoproteins in P/S is in the tens of milligrams per milliliter.  As such, the observations 
of significant changes in P/S glycans observed here cannot be due to glycoproteins shed 
directly from cancer cells; almost certainly they are derived from alterations to one or 
both of the two major sources of P/S glycoproteins—namely liver glycoproteins or 
immunoglobulins (IgG molecules) secreted by the immune system [115], [116]. Such 
alterations are thought to be mediated by cytokines secreted from the tumor 
microenvironment and exist as part of an acute-phase inflammatory response [117], 
[133]–[137]. 
However, this is not to imply that liver glycoprotein and immunoglobulin glycan 
alterations are unimportant or lack a cancer-relevant pathological effect. Several cancer-
upregulated glycoforms that cancer cells have in common with glycans that are induced 
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on acute phase liver proteins and/or IgG molecules in the presence of cancer have been 
found to mediate specific immune-modulating effects—some of which overtly favor 
cancer progression: 
Galectins are a family of lectins that bind β-galactoside sugars within glycans and 
are known to modulate a variety of immunological processes involved in cancer [125], 
[138], [139]. Malignant T-cells in mycosis fungoides/Sezary syndrome have been found 
to resist galectin-1 mediated apoptosis because they both lack the CD7 receptors that 
carry the oligosaccharides recognized by galectin-1 and because they express sialylated 
core 1 O-glycans that promote galectin-1 resistance [140]. Poly-N-acetylactosamine-
modified core 2 O-glycans bind to galectin-3, reducing the affinity of tumor major 
histocompatibility complex (MHC) class I-related chain A (MICA) for the activating 
NKG2D receptor on natural killer (NK) cells, preventing tumor cell killing of core 2 O-
glycan expressing cancer cells [141]–[144]. Similarly, modification of MUC1 by poly-N-
acetylactosamine and subsequent binding by galectin-3 interferes with TRAIL-mediated 
killing of DR4-expressing cancer cells by NK cells [144]–[146]. But perhaps the best 
known example is the ability of excessive tumor cell surface sialylation to continually 
stimulate the inhibitory Siglec-7 receptor on NK cells, preventing their activation [144], 
[147]–[149]. 
In light of these discoveries, the fact that α2-6 sialylation of abundant 
plasma/serum proteins is both associated with metastasis and poor prognosis [150], 
[151] and, in our study, was not only elevated in lung cancer but predicted progression 
and all-cause mortality in the large lung cancer set may shed additional light on a means 
by which cancer potentially manipulates the immune system to groom the physiological 
landscape and carve out a metastatic niche: Rather than directly interacting (cell-to-cell) 
with NK cells, tumor cells may simply be able to send out cytokine signals that are picked 
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up by the liver and/or the immune system that alter the way that these nominally healthy 
tissues glycosylate their secreted proteins.  This could, for example, facilitate a large-
scale amplification of sialylated glycans that are able to continually activate Siglec-7 
receptors on NK cells, preventing them from killing tumor cells and allowing them to 
metastasize. The possibility that cancer cells may induce the abnormal glycosylation of 
the highly abundant liver glycoproteins and/or IgG molecules found in P/S as a shielding 
mechanism against innate immune detection during metastasis attempts has received 
very little attention, but may be worth investigating. Though speculative, this strategy 
could even potentially be deployed in cases where cancer cells deplete themselves of a 
glycan feature required for immune-cell recognition—such as fucosylation recognized by 
the TRAIL-mediate killing mechanism of NK cells [152]—but induce it on abundant P/S 
proteins, serving to “swamp out” the recognition mechanism of innate immune 
surveillance. 
The ability of α2-6 sialylation to predict lung cancer progression and survival is 
not unique among P/S glycans. Indeed, all five top-performing glycan nodes in the 
present study were able to predict progression and/or survival to a more limited extent 
than α2-6 sialylation. The prognostic capacity of β1-4 and β1-6 branching however, may, 
at least in part, be due to the fact that these glycan features simply create greater 
opportunity for sialylation.  Beyond this study, others have found that the sialyl Lewis X 
epitope (which displays α2-3 sialylation rather than α2-6 sialylation) predicts 
progression and survival in both small cell [153] and non-small cell lung cancer [154]–
[156]. Like the prognostic Veristrat markers [157]–[159], which are serum amyloid A 
proteoforms [160], elevated α2-6 sialylation in lung cancer may largely be due to an 
inflammatory response by the liver. But if, as described above, sialylation-based cloaking 
of tumor cells from the immune system plays an important role in the metastatic 
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process, α2-6 sialylation may turn out to play a causative, mechanistic role in lung cancer 
progression. 
 
3.5 Conclusions 
A molecularly bottom-up approach to plasma/serum (P/S) glycomics based on glycan 
linkage analysis that captures unique glycan features such as α2-6 sialylation, β1-6 
branching and core fucosylation as single analytical signals was employed to evaluate the 
behavior of P/S glycans in all stages of lung cancer and across various stages of prostate, 
ovarian and pancreatic cancers. Elevation of terminal (total) fucosylation, α2-6 
sialylation, β1-4 branching, β1-6 branching and outer-arm fucosylation markers were 
most pronounced in lung cancer in a stage-dependent manner, but these changes were 
found to be independent of the tumor tissue-of-origin.  Using a Cox proportional hazards 
regression model, the marker for α2-6 sialylation was found to predict both progression 
and all-cause mortality in lung cancer patients after adjusting for age, gender, smoking 
status and stage at which the sample was taken.  Interestingly, certifiably healthy P/S 
donors had markedly lower levels of α2-6 sialylation, β1-4 branching and β1-6 branching 
relative to cancer risk-matched controls.  While early detection is ideal, the information 
provided by this and related studies [117], [119]–[121], [127], [128], [133]–[137] suggests 
that pre-cancerous inflammation may be responsible for the elevation of many of the 
glycan features observed in the at-risk controls relative to the certifiably healthy 
donors—implying that the goal of preventing such a pre-cancerous state may be as 
important as preventing the transition from an at-risk state to stage I cancer. 
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Figure 3.1. Univariate distributions and associated ROC curves for the top five-
performing glycan nodes in the large lung cancer set. Letters above the data points in 
panels a-e indicate statistically significant differences between the six groups shown: any 
overlap in lettering between groups indicates a lack of significant difference between the 
groups (Kruskal-Wallis with Dunn’s post hoc test). ROC curves for lung cancer cases 
(separated by stage) and controls vs. certifiably healthy patients are shown in panels f-j; 
stage I-IV cancer patients vs. controls are shown in panels k-o.  ROC curve AUCs are 
provided in parenthesis next to the specified stages.  “NS” next to ROC curve AUCs 
indicates that the ROC curve does not show a statistically significant difference between 
the two groups being compared. Glycan node symbol definitions are the same as in 
Figure 2.1. 
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Figure 3.2. Univariate distributions and associated ROC curves for the top five-
performing glycan nodes in the large lung cancer set when data were normalized to the 
sum of endogenous hexoses or HexNAcs. Letters above the data points in panels a-e 
indicate statistically significant differences between the five groups shown: any overlap 
in lettering between groups indicates a lack of significant difference between the groups 
(Kruskal-Wallis with Dunn’s post hoc test). ROC curves for lung cancer cases (separated 
by stage) vs. controls are shown in panels f-j. ROC curve AUCs are provided in 
parenthesis next to the specified stages. “NS” next to ROC curve AUCs indicates that the 
ROC curve does not show a statistically significant difference between the two groups 
being compared. Glycan node symbol definitions are the same as in Figure 2.1. 
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Figure S1: Univariate distributions and associated ROC curves for the top five-performing glycan nodes in the large lung cancer set when 
data were normalized to the sum of endogenous hexoses or HexNAcs. Letters above the data points in panels a-e indicate statistically 
significant differences between the five groups shown: any overlap in lettering between groups indicates a lack of significant difference 
between the groups (Kruskal-Wallis with Dunn’s post hoc test). ROC curves for lung cancer cases (separated by stage) vs. controls are 
shown in panels f-j.  ROC curve AUCs are provided in parenthesis next to the specified stages.  “NS” next to ROC curve AUCs indicates that 
the ROC curve does not show a statistically significant difference between the two groups being compared.   Glycan node symbol defini-
tions are the same as i  Fig. 1.
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Figure 3.3. ROC curves depicting the stage-dependent performance of the top five-
performing glycan nodes in distinguishing different types of cancer from controls or 
healthy individuals (a-e).  Adjacent to panels b-e are ROC curves from the large lung 
cancer study for comparison (f-i).  Clear stage-dependence is evident, regardless of the 
type of cancer involved. A comparison of each ROC curve at each stage in the large lung 
cancer study to the parallel ROC curve in a different type of cancer or different lung 
cancer sample set revealed no significant differences between ROC curves (DeLong’s 
test; see Table 2.8). A superscript “NE” (panels d and h) indicates that these data sets 
were normalized to the sum of endogenous hexoses or HexNAcs because heavy labeled 
internal standards were not added during analysis of the prostate cancer sample set. 
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Figure 3.4. Univariate distributions of the top five-performing glycan nodes within the 
control group of the large lung cancer set, subdivided on the basis of smoking status.  
Letters above the data points indicate statistically significant differences between the 
three groups shown: any overlap in lettering between groups indicates a lack of 
significant difference between the groups (Kruskal-Wallis; Bonferroni-corrected p-values 
< 0.0167 for within-group pairwise comparisons were considered statistically 
significant). 
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Figure 3.5. ROC curves illustrating the performance of top performing glycan nodes in 
distinguishing stage I lung adenocarcinoma from controls in the original set of samples 
(panels a and b) and the secondary set of samples (panels c and d). In panels a and c, 
data are normalized by sum of the hexoses or hexNAcs. In panels b and d data are 
normalized by t-Glc.  
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Figure 3.6. Multivariate logistic regression models for stage I-IV lung cancer patients 
from the large lung cancer data set.  Fully v lidated multivariate combinations of glycan 
nodes did not produce significantly better ROC curves in stage IV, III, II, or I lung cancer 
patients (panels a-d, respectively) compared to the best performing individual glycan 
node in the control specimens (DeLong test). Three separate curves are shown on each 
plot, corresponding to predicted probabilities derived from a multivariate logistic 
regression model 1) re-fitted at each iteration of cross-validation (referred to as “CV 
Probabilities (full)”), 2) fitted once on the complete dataset, fixing the predictors, but 
allowing parameter estimates to change at each iteration of cross-validation (referred to 
as “CV Probabilities (semi)”), and 3) fitted once on the complete dataset and taking the 
model-derived probability without use of cross-validation (referred to as “Fitted 
Probabilities”). 
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Figure 3.7. Univariate distributions of fucosylation-related glycan nodes, α2-6 
sialylation, β1-4 branching and β1-6 branching in stage 0 through stage IV liver fibrosis. 
No statistically significant differences were observed for any pairwise comparisons 
within a single glycan node (Kruskal-Wallis). 
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Figure 3.8. Large lung cancer data set progression (i.e., progression-free survival; a,c) 
and survival (all-cause mortality; b,d) curves for the top α2-6 sialylation quartile 
compared to all other quartiles combined. Panels a-b combine data from all stages; 
panels c-d present data from stage III only—illustrating that curve separation based on 
α2-6 sialylation is not simply driven by stage. Dotted lines represent 95% confidence 
intervals, colored according to their respective curves. Within each plot, progression 
curves were significantly different from one another (log-rank Mantel-Cox test; p < 0.01) 
as were the survival curves (log-rank Mantel-Cox test; p < 0.05).  For the progression 
data (all stages; panel a), the median duration of follow-up for those that progressed, 
until progression, was 6.9 months (17.1 months median total follow-up time); for those 
that did not progress, the median duration of follow-up was 22.7 months. Results from 
Cox proportional hazards models are described in the Results section. 
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Table 3.1. Composition of sample sets and their sub-cohorts. 
 
 
 
a Nominally Healthy donors were self-reported as healthy and were only age and gender-
matched to cases. 
b Age & gender-matched to cases; smoking status-matched in lung cancer sets; benign 
nodule positive in Stage I Lung Adenocarcinoma set; benign inflammatory condition-
matched in Pancreatic Cancer set 
c These samples were analyzed immediately prior to—but in a separate set of batches 
from the Large Lung Cancer set. Results for the quality control specimens analyzed in 
both sets of batches were not significantly different from one another. 
d Heparin is a glycosaminoglycan, but for reasons explained in the Methods section, it 
does not impact the results of glycan node analysis 
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Table 3.2. Basic clinical characteristics and n-values of the large lung cancer and 
certifiably healthy living kidney donors sample sets. 
 
a These specimens were collected as part of a separate study, see Methods section for 
additional details 
b Age in years ± S.D. 
c Significantly different from Controls and Cases (Kruskal-Wallis with Dunn's posthoc 
test; p < 0.0001) 
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Table 3.3. Statistically significant differences between cohorts within the 
large lung cancer study. Hexose data were normalized to heavy, stable isotope 
labeled glucose (Glc) and HexNAc data normalized to heavy, stable isotope labeled 
GlcNAc. 
a Kruskal-Wallis test followed by Benjamini-Hochberg false discovery correction 
procedure where significance at the 95% confidence level is given by p < 0.05. 
b “ns” indicates "not significant". “i” and “d” stand for “increased” or “decreased” in 
the clinically more-advanced cohort listed in the column header. i/d indicates p < 
0.05; ii/dd indicates p < 0.01, iii/ddd indicates p < 0.001, iiii/dddd indicates p < 
0.0001. 
c CH: Certifiably Healthy, C: Controls, I: Stage I, II: Stage II, III: Stage III, IV: Stage 
IV 
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Table 3.4. Statistically significant differences between cohorts within the 
large lung cancer study. Hexose data were normalized to the sum of endogenous 
hexoses and HexNAc data were normalized to the sum of endogenous HexNAcs. 
a Kruskal-Wallis test followed by Benjamini-Hochberg false discovery correction 
procedure where significance at the 95% confidence level is given by p < 0.05. 
b “ns” indicates "not significant". “i” and “d” stand for “increased” or “decreased” in 
the clinically more-advanced cohort listed in the column header. i/d indicates p < 
0.05; ii/dd indicates p < 0.01, iii/ddd indicates p < 0.001, iiii/dddd indicates p < 
0.0001. 
c CH: Certifiably Healthy, C: Controls, I: Stage I, II: Stage II, III: Stage III, IV: Stage 
IV 
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Table 3.5. Stage-by-stage comparison of the top performing glycan nodes. 
Comparisons are made for the large lung cancer set vs. other independent lung cancer 
sets (stages IV and I), ovarian (stage III) or prostate cancer (stage II). Actual ROC curves 
are shown in Fig. 2.5. 
a NS indicates no significant difference between ROC curves. 
b p-value is the result of Bootstrap test since the Delong’s test should not be applied to 
ROC curves with opposite directionalities 
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CHAPTER 4 
ALTERATION OF SERUM GLYCAN FEATURES IN BLADDER CANCER 
4.1 Introduction 
Urothelial cell carcinoma (UCC) or bladder cancer is one of the top ten causes of cancer 
deaths annually [161]. From a clinical perspective, there are two major forms of this 
cancer: 1) non-muscle-invasive bladder cancer (NMIBC; stages pTa/pT1/pTis) and 2) 
muscle-invasive bladder cancer (MIBC; stages pT2+). Early detection of bladder cancer 
is very important; patients with non-muscle-invasive tumors have a much higher 5-year 
survival rate (88% for NMIBC patients relative to 41% for MIBC patients) [162]. Yet 
despite the stage at which it is diagnosed, high recurrence rate is one of the essential 
characteristics of this cancer [163]. Therefore, even if diagnosed at early stages and 
treated, former bladder cancer patients need to be monitored frequently. Currently, the 
common methods for detecting bladder cancer are cystoscopy (which is invasive and 
expensive[164]), urine cytology (which has low sensitivity for low-grade bladder cancer 
[165]), and computed tomography (CT) screening (which may not detect small 
tumors[166]). Accordingly, there has been a wide search for new biomarkers that are 
noninvasive, cost effective, and can outperform cytology [167]–[170]. At present there 
are no clinically employed serum-based markers for monitoring patients after their 
treatment. Plasma and serum (P/S) glycomics represents a promising source for a new 
generation of cancer markers [93]. Aberrant glycosylation is a universal feature of cancer 
[90] where it appears to enable the ability of tumor cells to avoid innate immune 
detection [171]. The changes in structure and abundance of glycans are often caused by 
dysregulated glycosyltransferase (GT) activity [49]. Conceptually, a glycan analysis 
technique that could provide one-to-one surrogate data for abnormal GT activity using 
routinely available clinical samples and that relied upon existing clinical technology 
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could be quite valuable. 
As described above, in 2013, we developed a molecularly bottom-up approach 
that, unlike other approaches used in P/S glycomics, focuses on the analysis of 
monosaccharide and linkage-specific glycan “nodes” instead of intact glycans [88], [106], 
[107], [172]. It does this by employing the principles and processing chemistry of glycan 
methylation analysis (i.e., linkage analysis; Figure 2.2) to unfractionated P/S. This 
pools together each unique monosaccharide-and-linkage-specific glycan feature or 
glycan “node” from across all the normal and aberrant glycan structures in a given 
sample, providing a more direct surrogate measurement of GT activity than any single 
intact glycan. Moreover, many of these glycan nodes correspond directly and 
quantitatively to interesting glycan features such as “core fucosylation”, “bisecting 
GlcNAc”, and “β1-6 branching”—all captured as single GC-MS chromatographic peaks 
(Figure 2.1). 
Our large lung cancer study provided important information about diagnostic 
and prognostic value of serum glycans in cancer [172]. To examine the potential clinical 
utility of this approach in the context of UCC, we applied glycan node analysis to 152 
samples including 30 samples from certifiably healthy living kidney donors, 72 samples 
from patients with a history of bladder cancer but currently exhibiting no clinical 
evidence of disease (NED), 38 samples from patients with non-muscle-invasive bladder 
cancer, and 12 samples from patients with muscle invasive bladder cancer. Subsequently, 
we evaluated both the diagnostic and prognostic capacity of glycan “nodes” as clinical 
biomarkers. Elevated blood plasma protein glycosylation is known to be associated with 
inflammation in some non-cancerous clinical conditions [119]–[121]. Since C-reactive 
protein (CRP) is a well-studied marker of inflammation[173] as well as a prognostic 
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marker for UCC [174]–[177], we also evaluated the relationship between prognostically 
useful glycan nodes and CRP. 
4.2 Materials and Method 
4.2.1 Sample Information 
EDTA plasma samples from certifiably healthy living kidney donors as well as current 
and former UCC patients were enrolled in the Multidisciplinary Biobank at Mayo Clinic 
Arizona under a Mayo Clinic IRB approved protocol. Patients eligible for enrollment 
were those seen at Mayo Clinic Arizona who were ≥ 18 years old, able to provide 
informed consent, and undergoing evaluation as either a potential living kidney donor or 
for genitourinary diseases.  Detailed inclusion & exclusion criteria for living kidney 
donors are provided in Appendix A.  None of the living kidney donor patients smoked at 
the time of health screening and blood collection; 27% were former smokers and 73% 
never smoked. Living kidney donor and UCC patients were excluded if they declined to 
participate or if the banking of their biospecimens would compromise the availability of 
tissue for diagnosis and standard clinical care. All specimens were collected during the 
time frame of June 2010 through Feb. 2016. Standard operating protocols and blood 
collections were performed as previously described [108]. All specimens were stored at -
80 °C prior to shipment to ASU and maintained at -80 °C at ASU prior to analysis. All 
specimens were analyzed blind and in random order. An aliquot of plasma from the 
same individual donor was analyzed in every batch as a quality control (QC) specimen to 
ensure batch-to-batch consistency. 
 
4.2.2 Glycan Node Analysis 
Sample Preparation: Glycan node analysis was performed on the plasma samples as 
described previously (section 2.2.3). Briefly, it includes four main steps: 1) 
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permethylation, in which 9µL of plasma sample containing 1µL of a 10 mM solution of 
heavy-labeled D-glucose (U-13C6, 99%; 1,2,3,4,5,6,6-D7, 97%−98%) (Cambridge Isotope 
Laboratories), and N-acetyl-D-[UL-13C6]glucosamine (Omicron Biochemicals, Inc.) as 
the internal standard was mixed with 270µL of dimethylsulfoxide (DMSO) (Sigma-
Aldrich) followed by 105 µL of iodomethane (99%, Cat. No. I8507, Sigma-Aldrich). Then, 
this mixture was added to a plugged 1mL spin column (ThermoFisher Scientific, 
Waltham, MA, Cat. No. 69705) containing ~0.7g of sodium hydroxide beads (20–40 
mesh, Sigma-Aldrich) which had been preconditioned by acetonitrile (Fisher Scientific) 
and washed twice with DMSO prior to addition of sample. After occasionally stirring the 
NaOH column over 11 min, the unplugged samples were spun for 15 s at 5,000 rpm 
(2,400g) in a microcentrifuge to extract the permethylated glycans. In order to maximize 
glycan recovery, 300µL of acetonitrile was added to the NaOH column and spun down 
for 30 s at 10,000 rpm (9,600g). Then, in a silanized 13 × 100 glass test tube holding 3.5 
mL of 0.2 M sodium phosphate buffer, the solution from the first spin-through was 
added and mixed well. After pooling and mixing the second acetonitrile-based spin-
through solution was combined with the rest of the sample, followed by 1.2 mL of 
chloroform (Sigma-Aldrich). The test tube was then capped and shaken well, followed by 
removal and discard of the aqueous layer. After two additional rounds of liquid/liquid 
extraction, the chloroform layer was recovered and dried under nitrogen at 74 °C. 2) The 
second major step was TFA hydrolysis, in which 325 µL of 2M trifluoroacetic acid (TFA) 
(Sigma-Aldrich) was added to each test tube. After capping the samples and incubating 
them at 121°C for 2h, they were dried down under nitrogen at 74 °C. 3) The third major 
step involved reduction of sugar aldehydes, in which the samples were incubated for an 
hour after adding 475 µL of a freshly made 10 mg/mL solution of sodium borohydride 
(Sigma-Aldrich) in 1M ammonium hydroxide (Sigma-Aldrich). Then 63 µL of methanol 
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(Honeywell Burdick & Jackson) was added to each sample before drying at 74 °C under 
nitrogen. Next, 125 µL of a 9:1 (v/v) methanol: acetic acid solution was added to each test 
tube followed by drying under nitrogen. To fully dry the samples, they were then placed 
in vacuum desiccator for approximately 20 min. 4) The fourth major step consisted of 
acetylation of nascent hydroxyl groups, in which the sample residue in each test tube was 
dissolved by 18 µL water before adding 250 µL of acetic anhydride (Sigma-Aldrich). After 
sonicating the samples for 2 min and incubating for 10 min at 60 °C, 230 µL of 
concentrated TFA was added to each sample, followed by incubation of the capped 
samples for 10 min at 60 °C. Then, 2 mL methylene chloride (Fisher Scientific) was 
added to each sample followed by 2 mL of water. Next, liquid/liquid extraction was done 
twice in which the methylene chloride layer was saved and then transferred into a 
silanized autosampler (ThermoFisher Scientific), dried under nitrogen, reconstituted in 
120 µL of acetone (Avantor Performance Materials), and capped to be injected onto the 
GC-MS. 
Gas Chromatography-Mass Spectrometry: An Agilent Model A7890 gas 
chromatograph (equipped with a CTC PAL autosampler) was used coupled to a Waters 
GCT (time-of-flight) mass spectrometer to analyze the prepared samples. For all 
samples, one injection of 1µL was made at split ratio of 20:1 onto an Agilent split-mode 
liner containing a small plug of silanized glass wool with the temperature set to 280 °C. 
The DB-5ms GC column that was used for chromatography was 30 m. The oven 
temperature, initially kept at 165 °C, was increased at a rate of 10 °C/min up to 265 °C. 
Immediately after that, the temperature was increased at a rate of 30 °C/min to 325 °C, 
then held constant for 3 min. The transfer line to the mass spectrometer was kept at 250 
°C. Following the elution of sample components from the GC column, they were 
subjected to electron ionization (70 eV, 250 °C) and analyzed in the m/z range of 40-800 
  72 
with a scan cycle time of 0.1 s. Daily calibration and tuning of the mass spectrometer was 
done using perfluorotributylamine. 
The quantification method is described in detail elsewhere [88]. Briefly, summed 
extracted ion chromatogram peaks were integrated automatically and checked manually 
using QuanLynx software. The collected data were then exported to a spreadsheet for 
detailed analysis. 
 
4.2.3 Human C-Reactive Protein ELISA Assay 
The Invitrogen™ Human C-Reactive Protein ELISA kit (Catalog Number KHA0031, 
ThermoFisher Scientific) was used to measure the concentration of CRP in blood plasma 
samples from 30 certifiably healthy kidney donors, 72 patients with no evidence of 
disease, and 50 patients diagnosed with bladder cancer (38 NMIBC and 12 MIBC). The 
plasma samples were diluted 3000 times with standard diluent buffer. To prepare the 
standard solutions, Hu CRP standard was reconstituted to 8000 pg/mL using the 
standard diluent buffer. To make a 1200 pg/mL CRP solution, 300 µL of the 
reconstituted standard was added to a 2 mL eppendorf tube containing 1700 µL standard 
diluent buffer. Then, 300 µL of standard diluent buffer was added to each of the seven 
1.5 mL eppendorf tubes labeled as 600, 300, 150, 75, 37.5, 18.75, and 0 pg/mL CRP to 
make serial dilutions of the standard, making the concentration of each solution as 
labeled on their tubes. 
In order to perform ELISA, 100 µL of standards and pre-diluted samples were 
added to the appropriate wells of the antibody coated 96-well plate, leaving the wells for 
chromogen blanks empty. After covering the plate with a plate cover and incubating it for 
2 h at 37 °C, the solution was thoroughly aspirated and the wells were washed with 1X 
wash buffer for 4 times. Then, 100 µL of Hu CRP Biotin Conjugate solution was added 
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into each well except the chromagen blanks. The plate was then covered and incubated 
for 1 h at room temperature, followed by aspiration of the solution and washing the plate. 
Before adding 100 µL 1X Streptavidin-HPR solution into each well except the chromogen 
blanks, the Streptavidin-HPR (100X) was diluted by adding 10 µL of it to a tube 
containing 1 mL Streptavidin-HPR Diluent for each 8-well strip used in the assay. Then, 
the covered plate was incubated for 30 min at room temperature. After aspirating the 
solution and washing the plate, 100 µL stabilized Chromogen was added to each plate, 
turning the substrate solution blue. Following 30 min incubation in the dark, 100 µL 
stop solution was added to each well. After mixing the solution by tapping the side of the 
plate, the solution in the wells changes from blue to yellow. The absorbance was read at 
450 nm by Thermo Scientific Multiskan Go plate reader and the concentration of 
samples were calculated using SkanIt Software 3.2. 
 
4.2.4 Statistical Analysis 
Individual extracted-ion chromatographic peak areas for each glycan node were 
normalized using one of two possible approaches: 1) Individual hexose residues were 
normalized to heavy glucose and individual N-acetylhexosamine (HexNAc) residues 
were normalized to heavy N-acetyl glucosamine (heavy GlcNAc). 2) Individual hexose 
residues were normalized to the sum of all endogenous hexose residues. Likewise, each 
HexNAc residue was normalized to the sum of all endogenous HexNAcs. The average 
%CV calculated based on the analysis of the QC sample in each batch shows that the 
latter normalization method provides better within-batch reproducibility (< 10% for the 
top four performing glycan nodes) but the former normalization method performs better 
in separating the patient groups while still keeping the average inter-batch %CV in an 
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acceptable range (i.e., < 18%). Unless otherwise noted, results described below are based 
on normalization with heavy glucose and heavy GlcNAc. 
For both the glycan node data and the CRP ELISA data, outliers within each 
clinical group (Control, NED, NMIBC and MIBC) were removed after log10 
transformation using the ROUT method at Q = 1% by GraphPad Prism 7. After removing 
the outliers, the anti-log of each value was taken to reverse the transformation. To 
identify differences between clinical groups, the Kruskal-Wallis test was performed 
followed by the Benjamini-Hochberg false discovery correction procedure at a 5% false 
discovery rate using RStudio Version 1.0.143. Univariate distributions and ROC curves 
were plotted using GraphPad Prism 7. The ability of certain glycan nodes to predict 
bladder cancer recurrence was evaluated by performing Cox proportional hazards 
regression models using SAS 9.4. Correlations between CRP and glycan nodes were 
examined using Pearson correlation in GraphPad Prism 7. 
 
4.3 Results 
4.3.1 Altered Glycan Features in UCC 
The relative abundance of 19 glycan “nodes” was quantified in each of the control, NED, 
NMIBC, and MIBC patient samples. Each of these nodes contributed at least 1% of the 
sum total of all hexoses or all HexNAcs. Data normalized to heavy, stable isotope-labeled 
glucose and GlcNAc internal standards were first evaluated for statistically significant 
differences between all four patient groups.  Relative to the certifiably healthy controls, 
statistically significant changes were found in more than half of the glycan nodes 
measured in NED, NMIBC, and MIBC patients (Table 4.1). Among these glycan nodes, 
the only one that was decreased in the current and former cancer patient samples was 4-
linked glucose (i.e., 4-Glc, which is mostly derived from glycolipids). The same trend was 
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previously observed in lung cancer patient samples [172]. The rest of the altered nodes 
were increased in current and former UCC patients compared to the certifiably healthy 
controls.  
There were four glycan nodes that were most elevated in the current and former 
UCC patients relative to the certifiably healthy controls, including 6-linked galactose, 
2,4-linked mannose, 2,6-linked mannose, and 3,4-linked GlcNAc. These nodes 
correspond to α2-6 sialylation, β1-4 branching, β1-6 branching, and outer-arm 
fucosylation, respectively [88], [172]. The univariate distributions of these four glycan 
nodes in each of the four clinical groups are shown in Figure 4.1. ROC curves for 
current and former UCC patients vs. the certifiably healthy controls are also shown 
(Figure 4.1). The distribution of each of these glycan nodes within each cohort shows 
that patients with no evidence of disease (NED) have similar glycosylation profiles to 
patients with active disease (NMIBC and MIBC) and that significant increases in these 
glycan nodes can only be seen when comparing current and former UCC patient to the 
certifiably healthy controls—but not when comparing amongst the three current and 
former UCC patient subgroups (Table 4.1 and Figure 4.1). Data normalized to the 
sum of endogenous hexoses or HexNAcs were not as effective at distinguishing the 
control specimens from those from current or former bladder cancer patients (Table 
4.2 and Figure 4.2). However, as explained in the Discussion section, these data 
indicate that significant qualitative shifts in glycan composition are observed in current 
and former UCC patients as opposed to mere increases in the absolute abundance of 
glycans. 
 The average age of the certifiably healthy living kidney donors (controls) was 47, 
while the average age for the NED, NMIBC and MIBC patients was 74, 76, and 73, 
respectively. Yet, after correcting for multiple comparisons, no statistically significant 
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correlation of any glycan node with age could be found after pooling data from all 
cohorts and evaluating correlations for the age range in which there was overlap between 
the controls and the current and former UCC patients (i.e., ages 45-67; see Figure 4.3). 
Likewise, no significant correlations with age were observed within the certifiably 
healthy controls or within the current/former UCC patients when these groups were 
considered in isolation (not shown). 
 
4.3.2 Prognostic Value of Glycan Nodes 
Within the NED cohort there were numerous samples with high levels of specific glycan 
nodes that were well out of the range observed in the controls—and which were similar 
to the cancer patient samples—even though the NED patients were clinically free of 
disease (Figure 4.1). These observations led to evaluation of the ability of glycan nodes 
to predict recurrence in a Cox proportional hazards regression model. After breaking 
down glycan node data into quartiles and adjusting for age, gender, and time from 
cancer (i.e., time elapsed since there was evidence of cancer in a NED patient), 6-linked 
galactose and 2,6-linked mannose, which correspond to α2-6 sialylation and β1-6 
branching, respectively, predicted recurrence with p-values of < 0.05. The top α2-6 
sialylation quartile predicted recurrence from the NED state with a hazard ratio of 15 
relative to all other quartiles combined (lower bound at 95% CL = 1.3; upper bound at 
95% CL = 180; p = 0.029). Similarly, the top β1-6 branching quartile predicted 
recurrence from the NED state with a hazard ratio of 11 relative to all other quartiles 
combined (lower bound at 95% CL = 1.2; upper bound at 95% CL = 110; p = 0.037). The 
differences in the rates of recurrence for the top α2-6 sialylation and β1-6 branching 
quartiles compared to all other quartiles are shown in the progression-free survival 
curves (Figure 4.4). 
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4.3.3 CRP Correlation with Glycan Nodes 
CRP was measured in order to correlate changes in patient glycan nodes with patient 
inflammation status. The average level of CRP in the certifiably healthy controls was 1.76 
mg/L whereas the NED, NMIBC, and MIBC samples had average CRP levels of 3.84, 
3.21, and 3.08 mg/L, respectively (which are above the normal range of CRP (<3.0 
mg/L) [176]). The levels of 6-linked galactose, which corresponds to α2-6 sialylation, 
positively correlated with CRP (r=0.34, p < 0.0001), as did the levels of 2,6-linked 
mannose, which corresponds to β1-6 branching (r=0.38, p <0.0001) (Figure 4.5). 
 
4.4 Discussion 
Out of 19 quantified glycan nodes, four of them, each corresponding to a unique glycan 
feature including α2-6 sialylation, β1-4 branching, β1-6 branching and outer-arm 
fucosylation, were most significantly elevated in bladder cancer patients compared to 
certifiably healthy individuals (Table 4.1 and Figure 4.1). Interestingly, cancer-free 
patients with a history of UCC (NEDs) had glycan node distributions that were similar to 
both the early and late-stage cancer patients but distinct from the controls (Figure 4.1). 
And, unlike other types of cancers reported upon previously [172], glycan features were 
at the same level in later stages of UCC (MIBC patients) as in earlier stages (NMIBC 
patients). 
In order to interpret these findings, it must be understood that the glycans being 
measured are from high-concentration glycoproteins derived primarily from the liver 
(i.e., transferrin, alpha-2-macroglobulin, haptoglobin, etc) and the immune system (i.e., 
IgG antibody glycans) rather than being sloughed off or secreted by cancer cells 
themselves [115], [116]. These macro-level (mg/mL scale) changes in blood plasma 
glycan biochemistry are thought to be mediated by cytokines secreted from the tumor 
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which are recognized by the liver and/or immune system as part of a systemic 
inflammatory response, altering the way that these two major glycoprotein-producing 
systems glycosylate their proteins [117], [133]–[137]. 
With this in mind, there are three possible causes for the increases in various 
glycan nodes observed in Table 4.1 and Figure 4.1. First, the acute phase response in 
current and former UCC patients (evidenced by elevated CRP) may induce a net increase 
in the total concentration of plasma glycoproteins—and more glycoproteins means more 
glycans. Second, glycoprotein site occupancy may increase. While this possibility has not 
been extensively studied, some evidence exists that subtle but statistically significant 
increases in site occupancy may occur in steatosis and non-alcoholic steatohepatitis 
[178]. Third, the qualitative nature of the glycans themselves may change. This 
phenomenon has repeatedly been documented in cancer and is often the primary reason 
for shifts in glycan profiles—particularly when the data reported are compositional in 
nature (i.e., all signals sum to 100%) [120], [179], [180]. When the glycan node data from 
this study are normalized to the sum of endogenous hexose residues or HexNAc 
residues, statistically significant increases in the top four performing glycan nodes are 
observed in current and former UCC patients relative to the healthy controls (Figure 
4.2)—though these increases tend not to be as strong as when total glycan node 
quantities are considered (Figure 4.1)—i.e., when the data are normalized to heavy 
labeled internal standards. Altogether, elevated CRP levels and the data seen in Figure 
4.2 suggest that both the first and the third possible explanations likely contribute to our 
observations. Assessing changes in glycan site occupancy requires establishing a 
complex, custom assay for each protein in question and is beyond the scope of the 
present study. 
  79 
Overall, the glycan node distributions observed here in UCC suggest that UCC 
makes modest, early-stage alterations to blood plasma glycans that, even at stages III-IV, 
do not reach the extreme levels observed in pancreatic, lung, ovarian and other types of 
cancer [172] (Lung cancer patient glycan node data are compared side-by-side with UCC 
patient  glycan node data in Figure 4.6). Yet even in remission, most former UCC 
patients with no evidence of disease (NED), tended to maintain these modestly elevated 
blood plasma glycan levels—wherein the NED patients with the most highly elevated 
levels were most likely to experience relapse (Figure 4.4). 
It has previously been shown that serum glycans can be elevated in inflammatory 
patient states in the absence of cancer [119]–[121]. Moreover, chronic inflammation is 
known to be closely associated with the development of cancer [127], [128], [181]. 
Together with our observations, this suggests that the elevated plasma glycan levels 
observed in former UCC patients (currently in the NED state) that are prognostic of 
recurrence may be driven by or simply part of inflammatory processes. To assess this 
possibility, we measured CRP concentrations and found them to be strongly significantly 
correlated with levels of both α2-6 sialylation and β1-6 branching (Figure 4.5)—an 
observation that goes hand-in-hand with the fact that CRP has been found to predict 
UCC patient survival [176], [177]. 
This brings up the question of whether or not there is a mechanistic connection 
between alterations in plasma glycans (associated with inflammation) and the 
development or progression of cancer. There is evidence for the concept that the 
biological landscape experiences “grooming” or premetastatic “niche” formation prior to 
cancer establishing residence within the body [122]–[126]. And while glycans are not 
solely responsible for this process, evidence exists that they play important roles. As we 
have previously summarized [172] and others have explained in detail, cell-surface 
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glycans that facilitate resistance of galectin-mediated apoptosis [125], [138]–[140] 
(including poly-N-acetyllactosamine modified core 2 O-glycans [141]–[146]) as well as 
sialylated glycans that stimulate the inhibitory Siglec-7 receptor on natural killer cells 
[141]–[144] have important roles to play in helping cancer evade the body’s natural 
immunity. Using glycan node analysis, we have observed major changes in 
plasma/serum glycans in lung, pancreatic, and ovarian cancers [172] as well as in UCC 
(this study).  Further study is required to elucidate the potential mechanistic role of 
these macro-level changes to blood glycan biochemistry in the development and overall 
progression of cancer. 
 
4.5 Conclusions 
α2-6 sialylation, β1-4 branching, β1-6 branching, and outer-arm fucosylation were found 
to be significantly elevated in both current and former (in remission) UCC patients 
relative to certifiably healthy living kidney donors, with ROC curve c-statistics averaging 
approximately 0.8. In contrast to the stage-dependence that we have observed in other 
types of cancer [172], differences between patients with muscle invasive UCC, non-
muscle invasive UCC and patients in remission were not statistically significant. For UCC 
patients in remission, α2-6 sialylation and β1-6 branching were prognostic indicators of 
recurrence and were correlated with CRP levels (r = 0.34 & 0.38, resp.; p < 0.0001), a 
known prognostic marker in UCC. Though glycan nodes exhibited less stage-dependency 
in UCC than in other cancers [172], results highlighted the pronounced difference 
between the serum glycan biochemistry of healthy individuals vs. any stage of UCC 
(including remission) and underscored the concept (previously observed [172]) that for 
plasma glycans the transition between a healthy state and an at-risk state is much more 
pronounced than that between an at-risk state and early stage cancer. 
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Figure 4.1. Distributions and ROC curves for the best performing (most diagnostic) 
glycan node markers in distinguishing different sub-cohorts of UCC patients from 
healthy controls when data were normalized to heavy glucose or heavy GlcNAc. Patient 
distributions are shown in (a-d). The Kruskal-Wallis test was performed followed by 
Dunn’s post hoc test. The letters at the top of the data points show statistically significant 
differences between the patient groups; groups with same letter do not have a significant 
difference. (e-h) ROC curves for the different sub-cohorts of UCC patients vs. healthy 
individuals. Areas under the ROC curves are provided in parenthesis next to the stated 
patient groups. 
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Figure 4.2. Distributions and ROC curves for the best performing glycan node markers 
in distinguishing different forms of bladder cancer from healthy controls when data were 
normalized to sum of endogenous Hexoses or HexNAcs. Patient distributions are shown 
in (a-d). The Kruskal-Wallis test was performed followed by Dunn’s post hoc test. The 
letters at the top of the data points show statistically significant differences between the 
patient groups; groups with a common letter do not have a significant difference. (e-h) 
ROC curves for different groups of bladder cancer patients vs. certifiably healthy 
individuals. Area under the ROC curves are provided in parenthesis next to the stated 
patient groups. “NS” next to the area under the ROC curves shows that there is no 
significant difference between the two groups that are being compared. 
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Figure 4.3. Correlation between age and the best performing (most diagnostic) glycan 
node markers when data were normalized to heavy glucose or heavy GlcNAc. Pearson 
correlation was used to evaluate this correlation. The common age range between all 
cohorts was 45-67. “NS” next to the r-value indicates that the Pearson correlation was 
not statistically significant. Distribution of the healthy controls is demonstrated by red 
dots. Distribution of the different sub-cohorts of UCC patients is demonstrated by black 
triangles. 
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Figure 4.4. Bladder cancer recurrence curves for: (a) The top α2-6 sialylation quartile 
compared to all other quartiles combined. (b) The top β1-6 branching quartile compared 
to all other quartiles combined. In both panels, the recurrence curves within each plot 
were significantly different (log-rank Mantel-Cox test; p < 0.05). The median duration of 
follow-up for those that relapsed, until relapse, was 6 months, and for those that did not 
relapse was 12 months (The median total follow-up time was 11.75 months). The results 
of Cox proportional hazards models are reported in the Results section. 
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Figure 4.5. Correlation of CRP and glycan nodes. Log of CRP concentration vs. (a) α2-6 
sialylation; r = 0.34 and (b) β1-6 branching; r =0.38 are plotted. Both correlations are 
statistically significant (Pearson correlation; p < 0.01). 
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Figure 4.6. Distribution of the best performing glycan node markers in UCC with the 
MIBC group separated by patient stage. Data from a recently published lung cancer 
study [172] are displayed side-by-side for qualitative comparison. “SM Controls” 
indicates smoking status matched to the lung cancer patients. Letters at the top of each 
cohort show statistically significant differences between the patient groups; groups with 
a common letter do not have a significant difference. 
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Table 4.1. Statistically significant differences between controls and bladder cancer 
patient sub-cohorts. a 
 
 
a Individual hexose residues were normalized to heavy glucose and individual HexNAc 
residues were normalized to heavy GlcNAc) 
b Significance was determined by the Kruskal-Wallis test followed by the Benjamini-
Hochberg correction procedure at a 5% false discovery rate. 
c “ns” stands for “not significant”. “i” and “d” stand for “increased” or “decreased” 
glycan levels in the cohort with clinically more advanced disease listed in the column 
header. “i” or “d” indicates p < 0.05, “ii” or “dd” indicates p < 0.01, “iii” or “ddd” 
indicates p < 0.001, and “iiii” or “dddd” indicates p < 0.0001. 
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Table 4.2. Statistically significant differences between controls and bladder cancer 
patient sub-cohorts with data normalization to the sum of all endogenous hexoses or 
HexNAcs. 
a Significance was determined by the Kruskal-Wallis test followed by the Benjamini-
Hochberg correction procedure at a 5% false discovery rate. 
b “ns” stands for “not significant”. “i” and “d” stand for “increased” or “decreased” 
glycan levels in the cohort with clinically more advanced disease listed in the column 
header. “i” or “d” indicates p < 0.05, “ii” or “dd” indicates p < 0.01, “iii” or “ddd” 
indicates p < 0.001, and “iiii” or “dddd” indicates p < 0.0001. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
In this dissertation, we assessed the behavior of P/S glycans in different types of cancer 
across various stages by applying our molecularly bottom-up P/S glycomics approach 
known as “glycan node analysis” to over a thousand clinical P/S samples from different 
case control studies across all stages of cancer. Before initiating the studies on cancer 
sample sets, in order to validate the robustness of our method, glycan nodes were 
analyzed in a matched collection of serum and several different types of plasma to 
determine whether subtle differences in sample matrix impacted the analytical results. 
Sodium citrate and sodium EDTA plasma samples were excluded from the studies since 
their results were not consistent with serum and other types of plasma samples. 
Furthermore, analysis of glycan nodes from samples treated in different conditions 
relative to controls that were stored at -80 °C the whole time, suggested that glycans are 
fairly stable in plasma and serum. 
In lung cancer, the top performing glycan nodes in distinguishing cases from 
controls were including terminal (total) fucosylation, α2−6 sialylation, β1−4 branching, 
β1−6 branching, and outer-arm fucosylation. The elevation of these markers were stage 
dependent, yet independent of the tumor tissue-of-origin (when compared to ovarian, 
prostate, and pancreatic cancer). Out of these top performing glycan features, α2−6 
sialylation was able to predict both progression and all-cause mortality in lung cancer 
patients using a Cox proportional hazards regression model adjusted for age, gender, 
smoking status, and cancer stage. Moreover, markers such as α2−6 sialylation, β1−4 
branching, β1−6 branching were significantly increased in risk-matched controls relative 
to certifiably healthy living kidney donors. 
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In bladder cancer, markers for α2-6 sialylation, β1-4 branching, β1-6 branching, 
and outer-arm fucosylation were able to separate current and former (NED) cases from 
certifiably healthy controls; but since patients with a history of UCC had similar glycan 
distributions to both early and late stage cancer patients (which unlike other types of 
cancers mentioned earlier, had the same level of glycans), NED, NMIBC, and MIBC were 
not distinguished from one another. Furthermore, Using a Cox proportional hazards 
regression model adjusted for age, gender, and time from cancer, α2-6 sialylation and 
β1-4 branching were found to predict recurrence from the NED state and were correlated 
with CRP levels. 
Comparing our findings from the lung cancer study to the bladder cancer study, 
we realized that the glycan node levels in UCC do not alter in a stage-dependent manner; 
unlike lung and other types of cancers involved in the lung cancer study. They modestly 
alter in early stage UCC and even at stages III-IV do not reach the extreme levels 
observed in other types of cancer. The reason for this behavior in P/S glycans of UCC 
patients is not fully understood and needs to be further studied. 
Our observations together with the information provided by other studies [119]–
[121], [127], [128], [181] suggest that the elevated levels of many glycan features in the at-
risk controls (lung cancer study) as well as former UCC patients (NEDs) is driven by or 
simply part of inflammatory processes. These differences in the at-risk controls and 
former UCC patients compared to healthy individuals support the idea that the biological 
landscape undergoes “grooming” or premetastatic “niche” formation prior to cancer 
development within the body [122]–[126]. Further study is required to elucidate the 
potential mechanistic role of these changes to blood glycan biochemistry in the 
development and overall progression of cancer. 
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Mayo Clinic Arizona Guidelines 
Inclusion Criteria 
 All persons that wish to be considered as a potential living donor will be 
evaluated using the following criteria: 
• Age:  
1) Between the ages of 18-70. 2) Those above age 70 will be considered on 
a case-by-case basis. 
• BMI and Blood Glucose:  
Based on “Evaluation of Living Kidney Donor: BMI and Glucose 
Metabolism Guideline”: 1) Impaired Fasting Glucose (FBS > 100 and < 126) or 
IGT (2 hour BS > 140 and < 200) is a relative contraindication to donation. 
Patients with family history of diabetes, gestational diabetes and/or metabolic 
syndrome may be at higher risk than others for developing DM. 2) Prospective 
donors meeting these criteria require counseling about increased risk of 
developing DM and its consequences. 
• Blood Pressure:  
1) All patients worked up at Mayo Clinic will complete either a 24 hour 
blood pressure monitor, a blood pressure taken on at least two different 
occasions, or overnight BP monitoring to be analyzed. 2) Criteria for the 
diagnosis of Hypertension are including clinic or hypertensive therapy nurse 
blood pressure > 140/90 mm Hg, ABPM awake period (mean value) > 135/85 
mm Hg, ABPM overall (mean value) > 130/80. 3) Donors need to have normal 
blood pressure; however, hypertension may be acceptable if all the following 
conditions are met: greater than age 40, Caucasian, GFR meets “Evaluation of 
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Living Kidney Donor: GFR Protocol”, and hypertension controlled with one drug 
+ diuretic. 
• Kidney Function: 
GFR Standards need to be followed based on “Evaluation of Living Kidney 
Donor: GFR Protocol”. 
• Malignancy:  
Guidelines can be found at “Evaluation of the Living Kidney Donor: 
Donor Malignancy Guideline”. 
• Crossmatch/ABO: 
Donors in Arizona and Florida: See “Living Donors Blood Type, Subtype 
Determination Policy” and “ABO Verification for Living Donors” Policy. Donors 
in Rochester: See “ABO Blood Group and Other Vital Data Compatibility 
Verification Guideline”. 
• Pulmonary Nodules: 
Guideline can be found at “Evaluation of the Living Kidney Donor: 
Pulmonary Nodules Guideline”. 
• Stones: 
Guidelines can be found at “Evaluation of the Living Kidney Donor: 
Donor Nephrolithiasis Guideline”. 
• Microscopic Hematuria:  
Guidelines can be found at “Evaluation of the Living Kidney Donor: 
Donor with Microscopic Hematuria Guideline”. 
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• Polycystic Kidney Disease:  
Guidelines can be found at “Evaluation of the Living Donor: Polycystic 
Kidney Disease Guideline”. 
• Psychiatric:  
Guidelines can be found at “Evaluation of the Living Donor: Psychiatric 
Evaluation policy”. 
• Donor Coercion:  
Guidelines can be found at “Evaluation of the Living Donor: Coercion 
Guideline”. 
Exclusion Criteria 
• The transplant center may exclude a donor with any condition that, in the 
hospital’s medical/ethical judgment, causes the donor to be unsuitable for organ 
donation. 
• The transplant center will exclude all donors who meet any of the following 
exclusion criteria: 1) Is less than 18 years old. 2) Is mentally incapable of making 
an informed decision. 3) History of HIV. 4) Infectious Disease that can be 
transmitted through transplantation. 5) Active malignancy, or incompletely 
treated malignancy. 6) High suspicion of donor coercion. 7) High suspicion of 
illegal financial exchange between donor and recipient. 8) Evidence of acute 
symptomatic infection (until resolved). 9) Uncontrolled diagnosable psychiatric 
conditions requiring treatment before donation, including any evidence of 
suicidality. 10) Uncontrollable hypertension or history of hypertension with 
evidence of end organ damage. 11) Diabetes mellitus. 12) Consider on an 
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individual basis, usually not accepted as donor: non-Caucasian with 
hypertension, other antihypertensive regimens, family history of hypertensive 
kidney injury, evidence of end organ damage such as Left Ventricular 
Hypertrophy (LVH), additional risk factors particularly active smoking. 
Additional Information Regarding Living Kidney Donor Selection 
Donor Screening 
• A potential donor will be screened by the living donor coordinator on the phone 
or by completing an electronic form.  
• In addition, a social work interview is to be conducted for all potential donors if 
requested by the living donor coordinator.  
• At that point, blood type and tissue typing will be obtained and reviewed by the 
donor team. 
• If suitable, potential donor will be scheduled for an evaluation.  
Donor Evaluation 
Living donor candidate workups are valid for a duration of 18 months after being 
accepted at selection conference; thereafter, any repeat testing necessary will be 
determined by the evaluating team at the donor site after which the candidate will again 
be presented at selection conference. 
Workup of the donor will include: 
• Labs:  
1) CBC with differential. 2) PT/INR and PTT. 3) Renal Profile (BUN, 
Creatinine, Electrolytes). 4) Fasting glucose and A1C. 5) Liver function profile. 6) 
Thyroid Stimulating Hormone. 7) Fasting Lipid Profile. 8) Serum protein 
electrophoresis for age >60. 9) Oral glucose tolerance test for high risk patients 
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per the “Evaluation of Living Kidney Donor: BMI and Glucose Metabolism 
Guideline”. 10) HCG Quantitative blood (female < 55). 
• Serologies:  
See “Infectious Disease Protocol”. 
• Clearance Studies and 24 hour urine collection:  
1) Spot micro albumin/creatinine ratio. 2) Iothalamate GFR clearance and 
24 hour creatinine clearance. 
• Urine tests:  
1) Routine urinalysis. 2) Midstream Gram stain and culture. 3) Urine 
microscopy. 4) Stone risk profile for any donor with history of nephrolithiasis per 
the “Evaluation of Living Kidney Donor: Donor Nephrolithiasis Guideline”. 
• Other tests: Chest x-ray, EKG, Exercise Stress Echo (> 60 years or high cardiac 
risk) (>50 with hypertension or tobacco use) and/or dobutamine or nuclear 
stress test if clinically appropriate (may consider for younger patients on case to 
case basis), Screening for Autosomal Dominant Polycystic Kidney Disease 
(ADPKD) (for related donors of ADPKD recipient) per the “Evaluation of Living 
Kidney Donor: Polycystic Disease Guideline”, CT angiography: renal protocol to 
determine: 1) Whether the kidneys are of equal size. 2) If the kidneys have 
masses, cysts, or stones. 3) If the kidneys have other anatomical defects. 4) 
Which kidney is more anatomically suited for transplant. 
• Cancer screening per American Cancer Society (ACS) guidelines:  
1) Mammogram (females ≥40 or if h/o breast cancer in pre-menopausal 
1st degree relative). 2) Cologuard (≥50 or family history) - first tier for low-risk 
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patients. 3) Females should have a Pap smear every three years, provided most 
recent Pap smear was normal. If most recent Pap smear was not normal, follow-
up should be according to the recommendations of the GYN service. 4) PSA: Age 
50 for men who are at average risk of prostate cancer and are expected to live at 
least 10 more years, Age 45 for men at high risk of developing prostate cancer. 
This includes African Americans and men who have a first-degree relative 
(father, brother, or son) diagnosed with prostate cancer at an early age (younger 
than age 65), Age 40 for men at even higher risk (those with more than one first-
degree relative who had prostate cancer at an early age). 5) Low-Dose CT scan for 
those at high risk for lung cancer (those who meet all of the following: 55 to 74 
years of age, have at least a 30 pack-year smoking history AND are either still 
smoking OR have quit within the last 15 years. (Note: A pack-year is the number 
of cigarette packs smoked each day multiplied by the number of years a person 
has smoked. Someone who smoked a pack of cigarettes per day for 30 years has a 
30 pack-year smoking history, as does someone who smoked 2 packs a day for 15 
years.) 
• Consultations:  
1) Nephrology (different physician from recipient if possible). 2) Living 
Donor Nurse Coordinator. 3) Social Services (different from recipient social 
worker if possible). 4) Nutrition. 5) Pharmacy. 6) Transplant Surgeon/Urologist. 
7) Consider Transplant Psychiatrist/Clinical Psychology Specialist. 8) 
Independent Living Donor Advocate. 
• Any additional tests, procedures, consults or biopsies needed to determine their 
candidacy is a part of the donor evaluation until the donor is ruled out as a donor. 
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Selection Conference 
• The final decision to proceed with donation made at the Selection Conference, 
which may include the following multi-disciplinary team members: transplant 
surgeons, nephrologists, independent living donor advocate, psychiatrist, social 
worker, dietitian, pharmacists, financial services and nursing personnel. 
• Cases will be presented to the Selection Committee once all appointments 
completed and all results available. 
• Results of testing and assessments will be reviewed by the multi-disciplinary 
Selection Committee, providing an opportunity for all members to raise concerns 
and discuss any issues regarding the donor's suitability. 
• The living donor’s suitability for donation will be thoroughly documented in the 
donor’s medical record. 
• The decision of the committee will be documented in the donor's medical record 
and communicated to potential donor by a member of the multidisciplinary team. 
• Any exceptions to the selection criteria must be approved by the Living Kidney 
Donor Selection Committee & the reasons for it thoroughly documented in the 
patient’s medical record. 
 
